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ABSTRACT
Some characteristics of the local tissue damage and inflammatory reactions
induced by snake venoms were analyzed in a mouse model. Tissue damage was
studied by intravital, light, and electron microscopic techniques, and by the use of
biochemical markers. Detailed information on the early development and dynamics
of local tissue damage was obtained by intravital microscopy. Main alterations were
microvascular plasma leakage, hemorrhage, blood flow disturbances, thrombosis,
and myonecrosis. A new technique for the quantification of myonecrosis in vivo was
established, based on the principle of MTT reduction. The method was tested for its
usefulness in the evaluation of antibody-mediated neutralization of myotoxicity.
The inflammatory response to venom included early lymphopenia and
neutrophilia, thrombocytopenia, with edema and leukocyte extravasation at the site
of injection. A rapid plasma peak of IL-6 was induced by venoms, as well as by
purified muscle-damaging and hemorrhagic toxins, in response to cellular damage.
The effects of a purified hemorrhagic toxin on cultured endothelial cells were
studied. The toxin was not directly lytic to these cells even at high concentrations,
and caused moderate cell detachment due to its metalloproteinase activity,
suggesting that the endothelial cell damage in vivo occurs via an indirect mechanism,
probably initiated by proteolytic degradation of the basal lamina of microvessels.
Myotoxin II from Bothrops asper venom was shown to lyse a variety of cell
types in culture, including myoblasts and endothelial cells. This property was
exploited in a cytotoxicity assay for the evaluation of myotoxin neutralization.
Heparin was found to be a potent inhibitor of its cytolytic activity, by forming
complexes, held at least in part by electrostatic interactions. The ability of heparin to
neutralize several related non neurotoxic phospholipase A2 myotoxins present in
crotalid venoms, was not dependent on its anticoagulant effect. Thus, non-
anticoagulant heparin has a potential as a therapeutic aid, which should be further
evaluated. The structural characteristic of the binding interaction of heparin with
myotoxin II were analyzed, indicating that a hexasaccharide is the minimal heparin
chain size required, and that both N-sulfate and O-sulfate groups participate in the
binding.
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1INTRODUCTION
Medical importance of venomous snakes
Human envenomations due to snakebites are a significant health problem,
especially in tropical regions of the world. As these regions mostly correspond to
underdeveloped nations, and since snakebites occur largely in remote rural areas,
epidemiological data are generally scarce and most likely underestimate the true
situation. Nevertheless, some available figures and estimations of incidence and
mortality reported for several countries might illustrate the magnitude of this problem.
The World Health Organization, analyzed in 1954 statistical data on deaths
caused by snakebites on a global basis (Swaroop and Grab, 1954). In this classical
report, an estimation of 30,000-40,000 deaths per year was obtained, with the highest
figures corresponding to Asia (25,000-30,000) and Latin America (3,000-4,000). The
global incidence of snakebites was estimated as 500,000 per year. More recent reports
indicate that snakebite mortality is still high in some areas of the world. Warrell and
Fenner (1993) estimated 20,000 annual deaths from snakebites in India, and 50,000-
100,000 annual deaths in the world. In Burma (Myanmar), 2,000 annual deaths were
reported in 1930 (15.4/100,000 inhabitants), while still 1,000 annual deaths
(3.3/100,000) were registered for 1980, currently constituting the fifth cause of death
in this nation (Lwin et al., 1985; Warrell, 1993). Cardoso et al. (1993) described data
from Brazil on 19,200 snakebites per year with 25% mortality in the pre-antivenom
era (original reports dated between 1911 and 1918), 23,470 cases with 2.3% mortality
in 1943, and 20,170 cases with 0.6% mortality in 1986-1989. In the tribe of Waorani
indians of Eastern Ecuador, it was estimated that 4% of all deaths were due to
snakebites (Larrick et al., 1978). Pugh and Theakston (1980) reported a snakebite
incidence of 497/100,000 with 12.2% mortality, and an estimated 10,000 annual
deaths, in savanna Nigeria.
In addition to being a cause of mortality, snakebites may lead to permanent
disability of the victim in a proportion of cases, due to the severe tissue damage
caused by the venom of some species. This point is further considered in the
following sections.
The relevance of venomous snakes as a cause of human morbidity and mortality
has been pointed out above. In addition, snake venoms are medically important from a
basic point of view. Biologically-active components present in these secretions,
selected through millions of years of evolutionary pressures (Davidson and Dennis,
1990), enclose a great potential as tools for the study and understanding of their
2pharmacological targets. For example, snake neurotoxins have been invaluable in the
study of voltage-regulated ion channels, neurotransmitter release, and nicotinic
acetylcholine receptor structure and function (Castle et al., 1989; Whittaker, 1990).
Cobra venom factor has been an important tool for the study of the complement
system and its role in a variety of pathological conditions (Harrison and Lachmann,
1986; Vogt, 1990). Bothrops jararaca venom was the tool that led to the discovery of
bradykinin (Rocha e Silva et al., 1949). Many snake venom enzymes and peptides are
exploited in the field of coagulation research (Stocker, 1990a; Kornalík, 1991),
diagnosis (Stocker, 1990b), and clinical applications (Furukawa and Ishimaru, 1990).
Undoubtedly, many interesting agents and actions still await to be discovered in the
toxic secretions of snakes (Dufton, 1993).
Venomous snakes and their venoms
About 15% of the approximately 2500-3000 known species of snakes are
venomous, and they can be taxonomically classified in five families: Viperidae,
Crotalidae, Elapidae, Hydrophiidae, and Colubridae (Mengden, 1983; Mehrtens,
1987). Of these, Viperidae, Crotalidae, and Elapidae are of major medical importance
(Warrell and Fenner, 1993).
Snake venoms are produced by a pair of specialized exocrine glands in the
mouth (Kochva et al., 1980) and are complex mixtures of molecules of different
chemical nature (Jiménez-Porras, 1970; Tu, 1977). For example, using sensitive
analytical separation techniques such as capillary electrophoresis, as many as 70
peptides can be detected in a single venom (Perkins et al., 1993). The best
characterized venom components include proteins (with or without enzymatic
activities) and peptides, which display a wide variety of pharmacological and toxic
actions. Historically, venoms from a given family have been classified according to
their main pharmacological activity, such as "neurotoxic", "hemotoxic",
"hemorrhagic", and so on. However, these categorizations are too simplistic, and seem
misleading in the view of present knowledge on the complexity of venom actions and
their heterogeneity among different species of a given family (Russell et al., 1975).
As pointed out by Warrell (1993) when referring to these classifications, "a more
critical attitude towards species diagnosis and the development of specific, sensitive
and practicable immunodiagnostic techniques has exposed many exceptions to this
simple scheme, which should now be abandoned".
The different activities of snake venoms can usually be attributed to particular
components or toxins, although it is possible that different toxins may act
3synergistically in inducing an effect, and that a given toxin may have more than one
activity (Jiménez-Porras, 1968, 1970; Kini and Iwanaga, 1986).
Local tissue damage induced by snake venoms
Venoms from many species of snakes are able to cause, in addition to major
systemic toxic effects, striking alterations at the site of injection, leading to a variable
degree of local tissue damage (Ohsaka, 1979). The local effects of snake venoms have
been classically defined as hemorrhage, myonecrosis, and edema (Tu and Homma,
1970; Ohsaka, 1979). The magnitude of these effects depends on the venom type, the
route and dose injected, and the host. In severe cases, the tissue damage may lead to
serious sequelae such as permanent tissue loss, disability or amputation (Rosenfeld,
1971; Ho et al., 1986b; Kerrigan, 1991; Nishioka and Silveira, 1992).
The recognition of the clinical importance of local tissue damage in snakebites
has motivated an increasing number of studies on its pathogenesis. It may be assumed
that a better understanding of the mechanisms of tissue damage will result in
improved therapeutic modalities. In addition, the action of toxins may reveal
mechanisms of cell and tissue injury that are common to other pathologic conditions.
In early studies, crude venoms were utilized. However, soon it became evident
that, in order to dissect the complex events leading to the development of tissue
lesions, the respective components had to be isolated and studied individually. Efforts
to isolate specific toxins responsible for the tissue-damaging activities of venoms have
resulted in the discovery of a number of proteins, some of which have been
extensively characterized at the structural and biochemical level. Nevertheless, the
relatively large number of studies dealing with the isolation and biochemical
characterization of venom components, does not parallel studies of their in vivo
pathogenic actions and mechanisms. For example, more than 50 different snake toxins
capable of inducing hemorrhage have been isolated and biochemically characterized,
but only few of them have been studied regarding the pathogenesis of their
hemorrhagic action in experimental models (Ownby, 1990).
It should be pointed out that, although the study of isolated toxins constitutes an
invaluable approach to dissect and analyze venom actions in detail, the effects
induced by whole, unfractionated venoms should always be considered as an
important reference frame. As stated above, particular venom actions might be the
result of synergistic effects of two or more components. As well, the induction of a
given effect by a particular isolated component is not necessarily informative of its
relative contribution or importance in the context of the crude venom actions.
4Like other pathological conditions, local tissue damage induced by venoms can
be studied by two basic types of approaches. One is to analyze material obtained from
human cases of snakebite, such as tissue biopsies and biological fluids, together with
the clinical signs and symptoms. This approach has many inherent limitations, as it is
mainly descriptive, with experimental manipulations being difficult to control.
However, it is most valuable, as it directly examines the effects of venoms in the
human. As an alternative, experimental animal models are utilized with the
assumption that the effects of venoms will be similar to those observed in man.
Although some examples of species differences in the susceptibility to tissue-
damaging toxins have been reported, they seem to be uncommon, and in general,
similar venom effects are seen in clinical cases and in animals commonly used for
research. Harris and coworkers have described that notexin, a potent pre-synaptic
neurotoxin and myotoxin from the venom of Notechis scutatus scutatus, causes much
more extensive muscle damage in the rat than in the mouse (Harris, 1991). Chang and
Tseng (1978) described that crotamine, a myotoxin from the venom of Crotalus
durissus terrificus, while having a potent action on mouse and rat muscle, did not
affect muscles from frog and chicken. Another exception might be the case of several
Micrurus spp. venoms, which induce muscle damage in mice (Gutiérrez et al., 1983;
1986b; 1993), although no clinical reports of muscle damage have yet appeared
(Harris and Cullen, 1990). Nevertheless, the possibility that some degree of muscle
damage has gone undetected in patients bitten by these species has not been ruled out.
Intense myalgia has been recently reported in patients envenomed by Micrurus
corallinus and M. frontalis (Coelho et al., 1992).
In addition to experimental animal models, cell cultures represent potentially
useful tools for the study of tissue damaging toxins, and have increasingly been
utilized in recent years (Hayes and Bieber, 1986; Hodges et al., 1987; Ziolkowski and
Bieber, 1992; Takacs et al., 1992; Brusés et al., 1993; Baker et al., 1993; Bultrón et
al., 1993b; and present work). The obvious advantage of these in vitro cellular
systems is the possibility to control variables in a more defined fashion. However, the
results cannot always be easily extrapolated to the in vivo situation, as cultivable cell
lines are often less differentiated than normal, fully mature tissues (for example
skeletal muscle myoblasts vs. mature muscle), or may correspond to anatomical sites
different from the tissues of interest (for example umbilical cord endothelial cells vs.
capillary endothelium in specific organs and tissues).
A number of snake toxins with the ability to induce local tissue damage have
been isolated. Although the knowledge on their structural and functional aspects is
5progressing, their precise mechanisms of action are still largely unknown. This is in
contrast with the case of snake toxins which act upon the nervous system, the
knowledge of their target structures and mechanisms of action being more advanced.
Tissue-damaging toxins isolated from snake venoms
The following section summarizes the current knowledge on the main three
types of local tissue-damaging venom components: hemorrhagic toxins, myotoxins,
and edema-inducing toxins. The experimental techniques commonly utilized for their
study are also shortly mentioned.
a. Hemorrhagic toxins
Many toxins capable of inducing hemorrhage at the site of injection or at distant
sites have been purified from the venoms of crotalids and viperids (Bjarnason and
Fox, 1988; Ownby, 1990). All these toxins are proteins and display variable degrees
of proteolytic activity in vitro, on general substrates such as casein or dimethylcasein.
The biochemical characterization of these enzymes has proven them to be zinc
metalloproteinases (Bjarnason and Fox, 1988). Few hemorrhagic toxins have been
sequenced to date (either directly or by their cDNA), although the number of available
sequences is rapidly increasing. The comparison of these sequences indicates that,
despite differences in molecular weight, all of them appear to be related through a
common ancestral gene, and do not bear similarity to any other known protein, except
for their zinc binding site (Hite et al., 1992a; Paine et al., 1992). Very recently,
however, a significant homology has been observed with a group of reproductive tract
proteins involved in the maturation of sperm and in sperm-egg fusion (Gomis-Rüth et
al., 1993; Bjarnason and Fox, 1993). On the basis of molecular weight, hemorrhagic
toxins can be classified into three groups, the "small" metalloproteinases (~25 kD,
200-205 amino acid residues), the "medium" (30-60 kD), and the "large" (60-90 kD),
the latter having a more potent in vivo activity (Bjarnason and Fox, 1988; Paine et al.,
1992; Kini and Evans, 1992).
A recently recognized structural feature of hemorrhagic toxins is the presence of
a disintegrin domain in the group of "large" toxins (Hite et al., 1992a; Paine et al.,
1992). Disintegrins are low molecular weight (5-9 kDa), cystein-rich peptides, found
in the venom of many snake species, which all contain an Arg-Gly-Asp (RGD)
sequence. This conserved sequence allows them to potently inhibit platelet
aggregation, and is now known to be the site of interaction with cellular integrins
(therefore the name disintegrins) (Gould et al., 1990; Scarborough et al., 1993). Thus,
6hemorrhagic toxins share a common precursor with disintegrin peptides (Hite et al.,
1992a; Paine et al., 1992; Kini and Evans, 1992) and can actually release disintegrins
by autoproteolysis (Takeya et al., 1993) . Since the "large" hemorrhagic toxins are
also the most biologically active, it has been speculatively hypothesized that the
disintegrin domain may function as a specific targeting unit for endothelium,
enhancing the efficiency of these metalloproteinases (Takeya et al., 1990). The recent
molecular cloning of several hemorrhagic toxins (Hite et al., 1992b; Bjarnason and
Fox, 1993; Moura-da-Silva et al., 1993) will allow to construct and express the
appropriate mutants to test this hypothesis.
During the last two decades, a proliferation in the number of purified
hemorrhagic toxins from snake venoms occurred. The relationship between their
proteolytic activity and the mechanism of hemorrhage was disputed during some time,
mainly due to two factors. On one hand, some of the toxins were initially described as
not being proteolytic. This apparent discrepancy was subsequently found to be caused
by the lack of sensitive substrates and by suboptimal assay conditions, and it is now
well established that all snake hemorrhagic toxins are metalloproteinases. On the
other hand, a lack of correlation between the in vivo hemorrhagic potency and the in
vitro proteolytic activity was observed, when using general substrates (i.e.,
Mandelbaum et al., 1984). However, further work demonstrated a better correlation
between enzymatic and biological activities of the toxins, by using more specific
substrates, such as glomerular basal lamina preparations or purified basal lamina
components (Ohsaka et al., 1973; Bjarnason et al., 1988). The demonstration of the
ability of purified hemorrhagic toxins to proteolytically degrade several major
extracellular matrix components in vitro, such as collagen type IV, fibronectin,
entactin/nidogen, and laminin (Baramova et al., 1989, 1990a, 1991; Bjarnason et al.,
1988; Shannon et al., 1989; Maruyama et al., 1992), has led to the proposal of a
mechanism of action based on the enzymatic digestion of basal lamina of the
microvasculature (Ohsaka et al., 1973; Bjarnason and Fox, 1988; Bjarnason et al.,
1988). Methods for the measurement of the proteolytic degradation of extracellular
matrix produced by endothelial cells in culture have been reported (Takacs et al.,
1992). In vivo studies analyzing the supramolecular organization of the extracellular
matrix constituents (Timpl, 1989; Yurchenco and Schittny, 1990) of capillaries, using
sensitive immunohistochemical and electron microscopic methods, should shed more
light on the precise mechanism of action. However, no such analyses have yet been
performed with hemorrhagic toxins applied in vivo.
7Several histopathological studies of the microvessel damage caused by purified
hemorrhagic toxins have been reported. By electron microscopic analysis of the
affected tissues, it has been confirmed that the basal lamina of capillaries is often
disrupted (Ownby et al., 1978, 1990; Ownby and Geren, 1987; Moreira et al., 1994).
However, another major in vivo finding is an extremely rapid effect on endothelial
cells, which undergo degenerative morphological changes that can progress until
complete ruptures or gaps are formed within the cells (Ownby et al., 1978; 1990;
Ownby and Geren, 1987; Moreira et al., 1994). The observation of this phenomenon
suggests the possibility that hemorrhagic toxins could have a direct action on
endothelial cells, as has been theoretically discussed (Ownby and Geren, 1987;
Ownby et al., 1990; Gutiérrez and Lomonte, 1989). Alternatively, endothelial cell
alterations might be an indirect consequence of the proteolytic degradation of their
extracellular matrix environment. Studies that evaluate the direct actions of purified
hemorrhagic toxins on cultured endothelial cells are lacking. A recent report
presenting evidence for the induction of apoptosis of endothelial cells in culture, as a
possible basis for the hemorrhagic action of venoms, is difficult to interpret, as it was
performed using crude venoms (Araki et al., 1993). Furthermore, apoptosis is an
active cellular process, often requiring gene expression (Sen, 1992; Williams and
Smith, 1993; Collins and Lopez, 1993), and thus, relatively long time, in comparison
to the speed by which endothelial cell damage and hemorrhage develop in vivo.
Indeed, any proposed mechanism of action for the hemorrhagic toxins should
consider the fact that microvessels lose their integrity in vivo within the range of a few
minutes (Ownby et al., 1990; and present work). In this regard,  it is of interest to
point out that the degradation of basal lamina constituents by hemorrhagic toxins in
vitro seems a relatively slow process: proteolytic degradation of the substrates is often
demonstrated using incubation times of 4 to 24 hr (Bjarnason et al., 1988; Shannon et
al., 1989; Baramova et al., 1990a, 1991). While this does not deny the role of
proteolysis in the hemorrhagic effect, its implications for the mechanism of action
have not been widely discussed in the literature. It might be that only partial or minor
cleavages on certain key constituents of the basal lamina are necessary to destabilize
the structural integrity of vessels. Another possibility, although entirely speculative,
could be that a few initial specific cleavages activate in turn an endogenous
mechanism, that would rapidly amplify the degradation of the basal lamina. Finally, it
is also possible that the proteolytic activity of hemorrhagic toxins on intact basal
lamina constituents in vivo would be higher than under artificial, in vitro conditions.
In conclusion, although the currently available evidence clearly points out at a
8hemorrhagic mechanism based on the proteolytic attack of vascular basal lamina, the
details of the process are still incomplete, especially in vivo.
Concerning the mode of erythrocyte extravasation induced by these toxins, two
alternatives exist, and evidence has been presented for both types of mechanisms,
apparently depending on the particular toxin. One alternative is hemorrhage per
diapedesis, in which red blood cells leave the vessels through the widened
intercellular junctions of endothelial cells. The other is hemorrhage per rhexis, in
which erythrocytes escape via true transcellular discontinuities or gaps formed within
the damaged endothelial cells, without an opening of their intercellular junctions
(Ownby, 1990). A hemorrhagic toxin purified from the venom of Trimeresurus
flavoviridis was shown to act per diapedesis (Oshio, 1984). On the other hand,
several hemorrhagic toxins isolated from the venoms of Crotalus atrox, C. horridus
horridus, Agkistrodon bilineatus, and Bothrops asper have been shown to induce
erythrocyte extravasation per rhexis (Ownby et al., 1978; 1990; Moreira et al., 1994).
Several methods have been developed for the quantification of the biological
potency of hemorrhagic toxins (reviewed by Bjarnason and Fox, 1988). The most
utilized is the skin assay of Kondo et al. (1960), which involves the intradermal
injection of varying amounts of the test substance in rabbits or mice, followed by a
measurement of the area of the hemorrhagic spot, viewed from the internal side of the
dissected skin. The potency (or activity) is expressed as the "Minimal Hemorrhagic
Dose" (MHD), which is arbitrarily defined as the amount of toxin that induces a
hemorrhagic spot of 10 mm in diameter, in a time of 2-24 hr, depending on different
researchers. The MHD values of different hemorrhagic toxins range from 0.04 to 11
µg (Ownby, 1990). An alternative method is based on the quantification of
hemoglobin in extracts of muscular tissue after injection of the tested agent (Ownby et
al., 1984a).
b. Myotoxins
Toxins that induce degeneration of skeletal muscle cells are also widely
distributed in snake venoms (Mebs et al., 1983). From a biological point of view, this
should not be surprising, as skeletal muscle comprises about 80% of the body mass of
mammals (Harris and Cullen, 1990), and since snake venoms are functionally
important not only for the killing of the prey, but also for its digestion (Dufton, 1993).
Muscle-damaging toxins have been classified into two to four groups, according to
different researchers: Ownby (1990) and Mebs and Ownby (1990) divided them into
two main groups, (1) small, basic, non-enzymatic myotoxins, and (2) phospholipase
9A2 myotoxins. Harris and Cullen (1990) included the same two groups, and an
additional group formed by (3) the cardiotoxins. Gutiérrez and Cerdas (1984) added
still a fourth group, including (4) hemorrhagic toxins that may damage skeletal muscle
fibers indirectly, perhaps through ischemia. These four main types of muscle-
damaging proteins, and their subgroups, are listed in Table 1.
Table 1: A classification of muscle-damaging toxins from snake venoms.
Group Characteristics
_______________________________________________________________
(1) Small myotoxins Basic, non-enzymatic, single chain peptides 
of  42-45 a.a.
(2) Cardiotoxins Basic, non-enzymatic, single chain proteins 
of ~60 a.a.
(3) PLA2 myotoxins
   a. neurotoxic Basic, single chain (~120 a.a.) or complexed 
proteins with PLA2 activity and presynaptic 
neurotoxicity.
   b. non-neurotoxic Basic, single chain (~120 a.a.) or dimeric 
proteins with PLA2 structure.
b'.  enzymatically-active Asp-49 PLA2s
b''. enzymatically-inactive Lys-49 (or other variant) PLA2s
(4) Indirect myotoxic factors May damage skeletal muscle by indirect 
mechanisms, perhaps through ischemia
(1) Small myotoxins:
The group of "small" myotoxins is formed by highly basic proteins composed of
42-45 amino acid residues, without any known enzymatic activity (Ownby, 1990;
Harris and Cullen, 1990). The basic character is a constant feature not only of the
small myotoxins, but also of almost all myotoxic proteins isolated to date (Table 1),
suggesting that positively charged amino acid residues on the toxins play a central
role in the mechanism of cell recognition and/or cell damage. Small myotoxins have
10
been isolated from several rattlesnake (Crotalus spp.) venoms, in which they appear
to be widely distributed, as shown by immunological detection (Bober et al., 1988).
 Two well characterized examples of this homologous family of peptides are
crotamine, from Crotalus durissus terrificus (Laure, 1975) and myotoxin a, from C.
viridis viridis (Ownby et al., 1976; Cameron and Tu, 1977). When injected into mice,
these small myotoxins cause immediate prostration, contracture of the hind limbs, and
respiratory distress. The earliest histopathological feature of skeletal muscle exposed
to these toxins is vacuolization, progressing to necrosis by 48 hr after injection. By
electron microscopy, it has been shown that this vacuolation is due to dilatation of the
sarcoplasmic reticulum and perinuclear space. Other cells in the tissue such as
fibroblasts and endothelial cells are not affected (Ownby et al., 1976; Ownby, 1990;
Mebs and Ownby, 1990). An interesting feature of small myotoxins is that they are
not cytolytic to muscle cell precursors such as myoblasts in vitro (Baker et al., 1993;
Brusés et al., 1993), despite their potent myotoxic action in vivo.
The molecular mechanism of action of these toxins is not completely
established. Both crotamine and myotoxin a have been shown to act on a Na+
channel, increasing the membrane permeability to this ion, on rat and mouse skeletal
muscle preparations (Chang and Tseng, 1978; Hong and Chang, 1985). This action
would allow the influx of Na+ and water, which in turn would cause swelling of the
endoplasmic reticulum, and eventually, necrosis of the muscle cell (Mebs and Ownby,
1990). Other researchers have proposed that these myotoxins act directly on the
sarcoplasmic reticulum, based on evidence for the in vitro interaction with the
sarcoplasmic reticulum Ca2+-ATPase (Volpe et al., 1986; Utaisinchareon et al., 1991;
Baker et al., 1991), and on the cytochemical detection of sarcoplasmic reticulum-
bound myotoxin a when applied onto muscle sections in vitro (Tu and Morita, 1983).
However, no evidence for toxin internalization in intact muscle fibers has yet been
presented in favour of this hypothesis.
Using a theoretical approach based on sequence comparisons of small myotoxins
and other natural myotoxic components, Kini and Iwanaga (1986) have speculatively
predicted that the site responsible for myotoxicity corresponds to the cationic region
at residues 2-10, which shows the charge pattern +00+++00+, and is followed by a
hydrophobic region. However, in vitro and in vivo studies using synthetic peptides
and chemical cleavage fragments of myotoxin a suggest that both the amino- and the
carboxy-terminal regions of this protein are implicated in the muscle-damaging action
(Baker et al., 1991).
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(2) Cardiotoxins:
Cardiotoxins (also named cytotoxins, membrane toxins, and direct lytic factors)
are a group of basic proteins of 60-62 amino acid residues, devoid of enzymatic
activity, and structurally homologous to the post-synaptic neurotoxins, or a-
neurotoxins (Dufton and Hider, 1991). These membrane-active proteins have been
found in the venoms of elapid snakes, including the cobras (genus Naja) and ringhals
(genus Hemachatus). The sequences of about 60 cardiotoxins have been determined.
Their three-dimensional structure is basically similar to that of a-neurotoxins, despite
the marked difference in their biological activities (Dufton and Hider, 1991; Rees and
Bilwes, 1993). The name cardiotoxin originates from the ability of these components
to cause cardiac arrest in vitro and in vivo (Harris and Cullen, 1990; Harvey, 1990).
However, they also act as general cytolytic agents towards many cell types, and thus,
are also referred to as cytotoxins (Kini and Evans, 1989a; Dufton and Hider, 1991).
Few studies on the myotoxic activity of cardiotoxins are available. Mebs (1986)
reported that cardiotoxins from Naja nivea and N. nigricollis lacked myotoxicity.
However, other studies, using cardiotoxins from the venoms of Dendroaspis jamesoni
(Duchen et al., 1974), Naja mossambica mossambica (d'Albis et al., 1988) and Naja
naja atra (Ownby et al., 1993), clearly indicate that skeletal muscle damage develops
at the site of injection. Microscopic examination of tissue after injection of
cardiotoxin-1 from N. n. atra revealed prominent myonecrosis, with rupture of the
plasma membrane in the area of wedge-shaped lesions (delta lesions), and
condensation of myofibrils into dense clumps, alternating with clear areas containing
some elements of the sarcotubular system and damaged mitochondria (Ownby et al.,
1993). The basal lamina of muscle cells was observed to remain intact during the
whole degenerative process, and capillary endothelial cells were also spared from
damage (Ownby et al., 1993). In vitro, membrane depolarization followed by visible
cell damage of cultured myotubes from chick embryos was obtained after exposure to
seven highly purified cardiotoxins (Hodges et al., 1987).
The molecular basis for the cytolytic action of cardiotoxins has been studied
intensively, but the nature of their membrane receptor or binding site has remained
elusive (Harvey, 1990; Dufton and Hider, 1991; Rees and Bilwes, 1993).
(3) Phospholipase A2 myotoxins:
Phospholipase A2 (PLA2; EC 3.1.1.4) myotoxins have been found in the
venoms of many snakes of the families Elapidae, Crotalidae and Viperidae
(Rosenberg, 1990). As indicated in Table 1, they can be divided into two main
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groups: (a) presynaptically neurotoxic and highly lethal myotoxic PLA2s, and (b)
non-neurotoxic, myotoxic PLA2s with low lethal activity (Mebs and Ownby,  1990).
(3a) presynaptically neurotoxic PLA2 myotoxins:
Some well characterized toxins of this group are notexin (Halpert and Eaker,
1975; Harris et al., 1975), taipoxin (Fohlman et al., 1976; Harris and Maltin, 1982),
and crotoxin (Fraenkel-Conrat et al., 1980; Gopalakrishnakone et al., 1984;
Kouyoumdjian et al., 1986). Besides having a potent presynaptic action (Cull-Candy
et al., 1976), which accounts for their high lethal activities (mouse i.v. LD50 values of
0.017, 0.002, and 0.025 µg/g for notexin, taipoxin, and crotoxin, respectively; Harris,
1991), these toxins induce prominent damage to skeletal muscle. Nevertheless, it is
interesting to note that presynaptically-acting PLA2s are not always myotoxic, one
example of this being b-bungarotoxin (Mebs and Ownby, 1990).
Notexin, a single chain PLA2 from Notechis scutatus scutatus, is probably the
best studied among this group of toxins, regarding its effects on muscle (Harris et al.,
1975, 1980; Harris, 1991; Harris and Johnson, 1978; Pluskal et al., 1978; Ng and
Howard, 1980; Helmke and Howard, 1986; Sharp et al., 1993; Hodgson et al., 1993).
It has a potent myotoxic action: an injection of 2 µg will completely necrose the
soleus muscle of a 150 g rat (Harris and Cullen, 1990). The morphological features of
muscle damage induced by both groups of PLA2s (neurotoxic and non-neurotoxic)
are generally similar (Harris and Cullen, 1990; Mebs and Ownby, 1990).
Degeneration of muscle fibers proceeds rapidly, and is evident by 0.5-3 hr. The
earliest alterations are hypercontraction of sarcomeres and the appearance of wedge-
shaped membrane lesions (delta lesions). Mitochondria also show signs of damage,
such as swelling, abnormal cristae, floccular degeneration, and disruption. Creatine
kinase (CK) and other enzymes are rapidly released from the damaged cells, and thus
elevations are detectable in blood plasma. The degenerative process is also
accompanied by an early edema (but not hemorrhage) and infiltration by phagocytic
cells. By 12-24 hr muscle fibers are totally destroyed, with a more amorphous and
hyaline appearance. The basal lamina is preserved throughout this process, as well as
the microvasculature. Immature satellite cells, situated between the basal lamina and
the plasma membrane of muscle fibers, are also left undamaged (Harris and Cullen,
1990; Mebs and Ownby, 1990). This is relevant since satellite cells are believed to be
responsible for the formation of myoblasts, myotubes, and the eventual regeneration
of skeletal muscle after necrosis, if conditions are adequate.
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In similarity with the small non-enzymatic myotoxins described above, the
neurotoxic PLA2 myotoxins are not cytolytic to immature muscle growing in culture
(Harris et al., 1980; Jiang et al., 1987; Harris and Cullen, 1990). An exception to this
is nigexine, a basic PLA2 found in the venom of Naja nigricollis, which shows a
broad cytotoxic activity (Chwetzoff et al., 1989a; Chwetzoff, 1990), in addition to its
neurotoxic and direct muscle damaging effects (Rowan et al., 1991).
 Again, receptor(s) and mechanism(s) by which these PLA2s induce muscle cell
necrosis have not yet been established. The role of enzymatic activity in myotoxicity
(and other pharmacological actions, including neurotoxicity) is still not clear, despite
efforts by many groups of researchers during the last 20 years (Rosenberg, 1986; Kini
and Evans, 1989b). In many cases, chemical modification of specific amino acids
have resulted in partial dissociations of the catalytic and pharmacological activities
(Rosenberg, 1986, 1990). This suggests that myotoxicity, as well as other toxic
actions, might be partially mediated by non-enzymatic mechanisms, contrary to the
original a priori assumption that the toxic effects would be caused by the enzymatic
activity. Based on sequence comparison data, it has been speculatively proposed that
the molecular region responsible for myotoxicity would be located at amino acid
residues 89-97, forming a cationic site followed by a hydrophobic stretch (Kini and
Iwanaga, 1986). However, no direct evidence in support of this has yet been reported.
In addition to myotoxicity and neurotoxicity, another potent biological action of
some of these PLA2s is an anticoagulant effect (Kini and Evans, 1987). The recent
achievements in the cloning and expression of some of these PLA2s (Hodgson et al.,
1993) should allow the construction of mutants, and clarify the understanding of their
structure-function relationship.
(3b) non-neurotoxic PLA2 myotoxins:
This group includes a growing number of enzymes found mainly in snakes of the
families Crotalidae and Viperidae. The lack of neurotoxicity is reflected by their low
lethal activity, which rather has been attributed to myoglobinuria and renal failure
(Mebs and Ownby, 1990). Some well characterized toxins in this group are the
myotoxic PLA2s found in several Bothrops spp. (Gutiérrez et al., 1984a, 1986a,
1991b; Homsi-Brandeburgo et al., 1988; Lomonte and Gutiérrez, 1989; Heluany et
al., 1992), Agkistrodon spp. (Mebs and Samejima, 1986; Johnson and Ownby, 1993),
and Trimeresurus spp. (Mebs and Samejima, 1986; Kihara et al., 1992) venoms.
As mentioned above, the morphological features of muscle damage caused by
these PLA2s are similar to those observed with their neurotoxic counterparts.
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Nevertheless, two notable differences with the neurotoxic PLA2s, regarding the mode
of muscle damage, open the possibility that the non-neurotoxic myotoxins may utilize
a different mechanism for myotoxicity. First, some myotoxins of this group have been
shown to be directly cytotoxic to immature muscle cells growing in vitro (Brusés et
al., 1993; Bultrón et al., 1993b; and present work), in contrast with the neurotoxic
PLA2 myotoxins. Second, a number of natural toxin variants (or isoforms) have been
found in this group, which, while clearly having PLA2 structure, are unable to
hydrolyze phospholipids due to changes in amino acid residues that are essential for
the catalytic mechanism. Since these isoforms still conserve the ability to damage
muscle, it is clear that the non-neurotoxic PLA2 myotoxins can induce myonecrosis
without the need of enzymatic activity. The first report of a myotoxin with PLA2
structure, but lacking enzymatic activity, is that of Bothrops nummifer myotoxin
(Gutiérrez et al., 1986a, 1989). Examples that followed include B. jararacussu
bothropstoxin I (Homsi-Brandeburgo et al., 1988; Cintra et al., 1993), B. asper
myotoxin II (Lomonte and Gutiérrez, 1989; Francis et al., 1991), Trimeresurus
flavoviridis basic proteins I and II (Yoshizumi et al., 1990; Liu et al., 1990; Kihara et
al., 1992), Vipera ammodytes ammodytin L (Krizaj et al., 1991), and Agkistrodon
contortrix laticinctus myotoxin (Johnson and Ownby, 1993; Ownby and Li, 1993).
With the exception of ammodytoxin L, in which a serine replaces the conserved
aspartate residue in position 49, all other enzymatically-inactive myotoxins that have
been sequenced to date possess a lysine in this position, and are therefore commonly
referred to as Lys-49 PLA2s. In addition, there are several Lys-49 PLA2s isolated
from snake venoms, on which no detailed information on their myotoxic activity is yet
available, but which are probably myotoxic, on the basis of their high structural
homology with known myotoxins of this group. Examples of these would be
Agkistrodon piscivorus piscivorus K-49 -the first Lys-49 PLA2 discovered-
(Maraganore et al., 1984; Dhillon et al., 1987; Scott et al., 1992), and a Lys-49 PLA2
of Trimeresurus mucrosquamatus (Liu et al., 1991). Conversely, enzymatically-
inactive myotoxic PLA2s that have not yet been sequenced, will most likely turn out
to be Lys-49 variants, or variants of other critical amino acid positions. This will
probably be the case of Bothrops moojeni myotoxins I and II (Lomonte et al., 1990a),
B. pradoi myotoxin I (Moura-da-Silva et al., 1991), and B. godmani myotoxin II
(Díaz et al., 1992). Indeed, work in progress on B. godmani myotoxin II indicates that
it is a Lys-49 variant (Raghuvir Arni and José María Gutiérrez, personal
communication).
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Although some Lys-49 PLA2s have been originally reported to possess a very
low enzymatic activity (usually below 0.1-1.5% of that of their Asp-49 counterparts),
it is now believed that Lys-49 variants are unable to perform enzymatic catalysis.
Using site-directed mutagenesis of the porcine pancreatic PLA2, it has been clearly
demonstrated that the single replacement of Asp-49 by Lys-49 (or Glu-49) results in
the complete abrogation of PLA2 activity (van den Bergh et al., 1989). Consequently,
the extremely low PLA2 activity found in many Lys-49 preparations, and originally
believed to be intrinsic (Maraganore et al., 1984), is most likely due to contaminating
traces of enzymatically-active isoforms (i.e. Asp-49) that are difficult to remove (van
den Berg et al., 1989; Scott et al., 1992).
Little progress has been achieved on the mechanism of action of this group of
non-neurotoxic PLA2 myotoxins. As in the case of their neurotoxic counterparts, the
primary site of action is believed to be the plasma membrane of muscle fibers. This is
suggested by the following indirect evidence: (1) the ultrastructural observation of
early membrane ruptures or discontinuities in affected muscle fibers (Gutiérrez et al.,
1984b; Johnson and Ownby, 1993); (2) the increased intracellular calcium
concentration in affected muscle tissue (Gutiérrez et al., 1984a; 1989); (3) the
immunodetection of myotoxins on the plasma membrane of muscle sections exposed
in vitro (Brenes et al., 1987); (4) the ability of myotoxins to disrupt various types of
liposomes (Gutiérrez et al., 1989; Díaz et al., 1991, 1992; Rufini et al., 1992; Bultrón
et al., 1993a; Pedersen et al., 1993); and (5) the lack of inhibitory effect of
endocytosis-blocking agents (ammonium chloride and chloroquine) on the cytolytic
damage induced by myotoxins in vitro (Bultrón et al., 1993b).
Contrary to the initial working hypothesis in which muscle damage was
attributed to the enzymatic hydrolysis of membrane phospholipids (Gutiérrez et al.,
1984a), it has now become clear that the membrane-damaging activity of these
myotoxins is exerted without the requirement of PLA2 activity. This is demonstrated
by (1) the ability of Lys-49 or Ser-49 variants to cause myonecrosis (Homsi-
Brandeburgo et al., 1988; Lomonte and Gutiérrez, 1989; Krizaj et al., 1991; Kihara et
al., 1992), and to disrupt liposomes (Díaz et al., 1991; Rufini et al., 1992); and in
addition, indirectly supported by (2) antibody-neutralization studies in which
myotoxins retain PLA2 activity after inhibition of myotoxicity (Lomonte et al., 1992),
or conversely, retain myotoxicity after inhibition of PLA2 activity (Lomonte et al.,
1987); and (3) the ability of enzymatically-active myotoxins to damage muscle in
vitro under conditions that inhibit enzyme activity, i.e. the chelation of calcium ion by
EDTA (Gutiérrez et al., 1986c; Bultrón et al., 1993a).
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Although PLA2 activity is clearly not required for membrane damage, several
observations indicate that PLA2 activity may have an enhancing role for some of
these toxins. For example, B. asper myotoxin I (enzymatically-active) is about 2-3
times more potent in inducing myonecrosis and in disrupting liposomes, compared to
the enzymatically-inactive myotoxin II (Díaz et al., 1991). Furthermore, when the
PLA2 activity of myotoxin I is inhibited in vitro by EDTA-chelation of calcium ion,
the liposome-disrupting activity decreases and becomes roughly similar to that of
myotoxin II, which is not affected by EDTA (Díaz et al., 1991). In agreement with
this, myotoxin III shows a reduced muscle-damaging activity in vitro when its PLA2
activity is inhibited by EDTA (Bultrón et al., 1993a). On the other hand, in the case
of Trimeresurus flavoviridis PLA2s, it has been recently described that Lys-49
myotoxins (basic proteins I and II) are about twice as myotoxic as the Asp-49
myotoxin (Kihara et al., 1992), indicating that the observations made with B. asper
myotoxins, regarding the role of PLA2 activity, cannot be extrapolated to all of the
myotoxins in this group.
Despite these recent advances towards understanding the mode of action of this
group of toxins, their membrane target(s) and the details of the membrane damage
remain unknown. Especially intriguing is the molecular basis of their selectivity for
skeletal muscle in vivo, which contrasts with their ability to affect a variety of cell
types in vitro (Brusés et al., 1993; Bultrón et al., 1993b; and present work).
In addition to their myotoxic action, several of these PLA2s induce edema
(Gutiérrez et al., 1986a, 1986c; Selistre et al., 1990), even in the absence of PLA2
activity, such as with B. asper myotoxin II (Lomonte and Gutiérrez, 1989; and present
work). The mechanism for edema induction in the absence of PLA2 activity is also
unknown. Furthermore, when PLA2 activity is present, these myotoxins, in similarity
with various other PLA2s (Kini and Evans, 1987) exhibit a potent anticoagulant effect
in vitro, prolonging the recalcification time of platelet-poor plasma (Gutiérrez et al.,
1986c; Díaz et al., 1991).
(4) Indirect myotoxic factors:
The first three groups of myotoxic factors described above, act directly upon
muscle fibers to induce their degeneration and eventual necrosis. In contrast, this
fourth group includes toxins that can induce local muscle damage, not via a direct
action, but most likely as a secondary consequence to the damage to
microvasculature, perturbations of blood flow, and development of ischemia. This
category includes some hemorrhagic toxins which have been reported to induce also
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muscle damage (Ownby et al., 1978; Fabiano and Tu, 1981; Queiroz et al., 1985a,
1985b; Yagihashi et al., 1986; Komori and Sugihara, 1988; Kamiguti et al., 1991). In
fact, hemorrhagic toxins may be a complicating factor in the assessment of the direct
muscle-damaging activity of crude venoms (Mebs and Ownby, 1990; Harris and
Cullen, 1990).
The myonecrosis observed after the injection of some hemorrhagic toxins
appears to develop more slowly (i.e. after about 4-6 hr) than that caused by direct
myotoxins, in agreement with the concept of ischemia as a cause of muscle
degeneration (Ownby, 1990). Furthermore, the morphology of muscle fibers that have
been damaged by hemorrhagic toxins also appears to be different, having a more
hyaline appearance (Yagihashi et al., 1986), also referred to as the "coagulative" type
of necrosis (Homma and Tu, 1971), as opposed to the "myolytic" appearance
described in the previous sections.
However, there may be exceptions to this concept of a slow development of
muscle damage caused by hemorrhagic toxins. For instance, some of them have been
reported to damage muscle fibres in 1 hr (Yagihashi et al., 1986). Another
complicating observation is that some toxins can cause extensive microvessel damage,
in apparent absence of skeletal muscle necrosis (Selistre et al., 1990). This suggests
that additional factors, besides damage to microvasculature, might be necessary for
the injury of muscle induced by some hemorrhagic toxins. Theoretically, among these
possible concomitant factors could be (1) the induction of edema (with consequent
tissue compression and ischemic action), (2) the effects on coagulation components,
and (3) on platelets, both being critical in the development of blood flow disturbances.
Although the role of ischemia in the development of myonecrosis due to
hemorrhagic toxins has been often proposed and/or assumed (Gutiérrez and Lomonte,
1989; Ownby, 1990; Ownby and Mebs, 1990; Harris and Cullen, 1990; Dos Santos et
al,. 1992), studies providing direct evidence for such a mechanism are still lacking.
These could include the evaluation of biochemical indicators of ischemia (for example
lactic acid and ATP levels; Harris et al., 1986), and the in vivo analysis of vascular
flow parameters (Harris and Cullen, 1990). Also, it should be possible to clearly
determine (or exclude) any eventual direct action of the toxins on muscle fibers by the
use of in vitro assays of muscle damage, such as the release of intracellular markers
from gastrocnemius or other muscle preparations (Gutiérrez et al., 1986b; Melo and
Suarez-Kurtz, 1987).
Several methods are available for the evaluation of myotoxic activity of venoms
and toxins, both in vivo and in vitro. A simple technique has been proposed for the
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quantification of the "necrotizing" activity of venoms (Theakston and Reid, 1983)
based on an intradermal injection and measurement of skin lesion after 3 days, but
this assay does not evaluate myonecrosis, and it is not clear what type of venom
components it is able to detect. Histological analysis of injected muscle tissue is
undoubtedly the reference method, and can be made quantitative (Ownby et al., 1982;
Kouyoumdjian et al., 1986; Ownby and Colberg,  1988; Preston et al., 1990; McLoon
et al., 1991). Nevertheless, quantitative histology requires considerable work and
equipment, and for this reason, many studies have utilized histological evaluation only
in a qualitative manner. As an alternative, methods based on the measurement of
biochemical markers of skeletal muscle damage have been utilized. These include the
quantification of specific intracellular enzymes released after cell injury, either by
measuring their increased activity in plasma (or serum), or their decreased
intracellular content in the affected muscle tissue. Among these enzymes, creatine
kinase (CK; EC 2.7.3.2) has been frequently utilized. This enzyme occurs in three
electrophoretically distinct isoforms, MM, MB, and BB, which are preferentially
expressed in skeletal muscle, cardiac muscle, and central nervous system, respectively
(Raphael, 1983). When total CK quantification is utilized in the study of skeletal
muscle damage induced by a given venom or toxin, it is important to verify that its
increase is due to the CK-MM isoenzyme (Nakada et al., 1980, 1984; Gutiérrez et al.,
1986a, 1986c; Chaves et al., 1989). Moreover, pharmacokinetic parameters such as
the distribution and plasma half-life of the enzyme may significantly influence the
results. Therefore, it is also important to select an optimal sampling time in these
determinations (Gutiérrez et al., 1980; Ownby et al., 1982). Time-course experiments
of the CK release after myonecrosis induced by non-neurotoxic PLA2 myotoxins
(Gutiérrez et al., 1984a, 1991b; Lomonte and Gutiérrez, 1989; Díaz et al., 1992), or
their corresponding crude venoms (Gutiérrez et al., 1980, 1984a; Melo and Suarez-
Kurtz, 1988; Chaves et al., 1989), have shown that, in general, the plasma peak
occurs between 1 and 3 hr after injection, rapidly declining thereafter.
The use of CK, or other enzyme markers, as estimators of muscle necrosis may
not necessarily be appropriate for all types of muscle-damaging toxins, since different
cytopathogenic mechanisms may participate in each case, as discussed above. It is
possible that CK, despite being an enzyme of considerable size (81 Kd), may be
released in reversible stages of cell injury, for example, as reported in the case of
myotoxin a, of the group of small myotoxins (Ownby et al., 1982). Suarez-Kurtz
(1982) has shown that CK can be released from frog skeletal muscle by osmotic
changes, in apparent absence of irreversible cell damage, as judged by
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electrophysiological criteria (quantification of muscle twitch amplitude). In the case
of Notechis scutatus venom, containing the presynaptically neurotoxic PLA2 notexin,
the correlation of muscle necrosis to increased plasma CK levels was not satisfactory
(Preston et al., 1990), although in this study the correlation was analyzed at 24 hr, a
time point in which the plasmatic CK levels were declining. Nevertheless, at least
with the group of non-neurotoxic PLA2 myotoxins, or venoms containing these
toxins, a fair correlation appears to exist between the amount of venom injected and
the plasma CK increase (Nakada et al., 1980; 1984; Gutiérrez et al., 1980; Mebs et
al., 1983). This might be a reflection of the type of mechanism utilized by such
myotoxins, which, as discussed above, presents some subtle differences with that of
neurotoxic PLA2s, and more obvious differences with that of small myotoxins. More
quantitative studies, using different venoms and myotoxin types, are needed to
analyze the validity of CK measurements in the assessment of myonecrosis. In
addition, other methods, ideally combining simplicity and reliability, should be
developed and evaluated.
Ex vivo, muscle preparations such as the mouse gastrocnemius or the rat
extensor digitorum longus muscles, have been utilized in the determination of
myotoxic activity, using the release of CK into the bathing solution as a marker of cell
damage (Gutiérrez et al., 1986c; Melo and Suarez-Kurtz, 1987, 1988). Some
advantages of these ex vivo systems over in vivo tests are the lack of influence of
enzyme distribution and half-life, the possibility to control variables in the bathing
solution, and the reduction of experimental animals by half, if muscles from both
extremities of a single individual are utilized.
In vitro, cell cultures of skeletal muscle myoblasts, myotubes, or even other cell
types, might have an interesting potential as models for the assessment of myotoxic
activity, at least for some myotoxin types. This area of research is still relatively new
and not fully exploited. If these cell culture systems prove to correlate well with in
vivo results, they could become invaluable simple substitutes of live animals for the
study of some myotoxins and their neutralization by antibodies or other types of
blocking molecules.
c. Edema-inducing toxins
Many types of snake venoms contain potent inflammatogenic factors that induce
a rapid and drastic edema response (Bonta et al., 1979; Tan and Saiffudin, 1990). One
important consequence of edema is tissue compression (Garfin et al., 1985) and the
resultant enhancing effect on the ischemic conditions that may arise at the site of the
20
bite, contributing in this way to the development of local tissue damage. In addition to
the local consequences, an edema of considerable magnitude will contribute to the
hypovolemic and hypotensive effects of venom that lead to cardiovascular shock.
Edema-inducing components in snake venoms are biochemically heterogeneous,
and may range from preformed biogenic amines of the histamine type (Tilmisany et
al., 1986) to small peptides or proteins such as phospholipases A2 (Vishwanath et al.,
1985, 1987, 1988; Marshall et al., 1989; Teng et al., 1989; Lomonte and Gutiérrez,
1989; Wang and Teng, 1990a, 1990b, 1991, 1992; Liu et al., 1991; Tan et al., 1991;
Ferrer and Moreno, 1992; Nair et al., 1993), esterases (Ohtani and Takahashi, 1983;
Oguchi et al., 1986; Teng et al., 1989; Wang et al., 1991), proteases (Teng et al.,
1989), kinin-releasing enzymes (kallikreins, kininogenases; Mebs, 1970; Vargaftig et
al., 1974; Bjarnason et al., 1983; Samel et al., 1987; Bailey et al., 1991), and lectins
(Lomonte et al., 1990b).
The edema induced by venom PLA2s has been intensively studied from the
pharmacological point of view, perhaps because considerable evidence has
accumulated in recent years to support the inflammatogenic role of human non-
pancreatic (extracellular) PLA2 in a variety of pathological conditions (Pruzanski and
Vadas, 1991), despite some still controversial observations (Morgan et al., 1993). As
this human enzyme shows close structural homology with those obtained from venom
secretions, especially group II PLA2s (Davidson and Dennis, 1990), the latter
enzymes, which are more readily obtainable, are being used as models for the assay of
potential inhibitors of inflammation (Marshall et al., 1989).
The majority of edema-inducing venom components probably promote
inflammation indirectly, by releasing or inducing potent autacoids. As an example,
many venoms, in all families of snakes, have been shown of being capable of
releasing histamine from animal tissues (Rothschild and Rothschild, 1979), which
would be responsible for the immediate phase of increased vascular permeability via
H1 receptors on endothelial cells (Trowbridge and Emling, 1989; Atkinson et al.,
1992), among other disturbances.
Later stages of edema are believed to be induced by several types of mediators,
including bradykinin, prostaglandins, and leukotrienes, acting in a complex
interrelated manner (Trowbridge and Emling, 1989). Bradykinin, a potent
hypotensive, pain-inducing, and microvascular permeability-increasing mediator
(Kozin and Cochrane, 1992), can be generated in response to venoms (Mebs, 1970,
1990; Rothschild and Rothschild, 1979; Bonta et al., 1979). Prostaglandins and
leukotrienes, which probably mediate the delayed, prolonged phase of vascular
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permeability increase (Trowbridge and Emling, 1989), have also been shown to be
induced by some venoms (Rothschild and Rothschild, 1979). Anaphylotoxins C3a and
C5a of the complement system, which have a potent action on vascular permeability,
are known to be released by the "cobra venom factor" of the Naja spp. snakes (Vogt,
1990).
All these findings suggest that the edema induced by snake venoms is
multifactorial in origin, and therefore, that no single inhibitor or drug would be
expected to counteract it (Bonta et al., 1979; Detrait and Jacob, 1988; Trebien and
Calixto, 1989). The diversity of mechanisms participating in the induction and
maintenance of edema is observed even at the level of single toxin components
(Calhoun et al., 1989; Marshall et al., 1989; Chen et al., 1990; Wang et al., 1991). As
an example, "TMV F-IV", an edema-inducing toxin purified from Trimeresurus
mucrosquamatus venom, has been shown to act by the release of histamine, serotonin,
arachidonate metabolites PGE2 and LTB4, platelet-activating factor (PAF), involving
the participation of both mast cells and neutrophils (Wang et al., 1991). Even in
studies with purified toxins, their relative contribution to the overall edema-inducing
activity of the crude venom has generally not been determined, and the purified
components may show lower activity than the crude venom.
Among the various mechanisms described in the induction of edema by purified
venom components are: mast cell degranulation with release of histamine/serotonin
(Chiu et al., 1989; Calhoun et al., 1989; Cirino et al., 1989; Wang  and Teng, 1990a;
Moreno et al., 1992; Lloret and Moreno, 1993), attraction of polymorphonuclear
neutrophils (Wang et al., 1991) with superoxide radical formation (Wang and Teng,
1991, 1992), induction of prostaglandins and leukotrienes (LTB4) in mast cells (Wang
et al., 1991), release of bradykinin (Cohen et al., 1970; Vargaftig et al., 1974; Teng et
al., 1992), release of a vasoactive peptide different from bradykinin (Oguchi et al.,
1986), induction of endothelium-derived relaxing factor (now identified as nitric
oxide; Kolb and Kolb-Bachofen, 1992) via bradykinin stimulation of endothelium
(Cirino et al., 1991), potentiation of bradykinin activity by peptide inhibitors of
angiotensin-converting enzyme (Ferreira et al., 1992), and release of slow-reacting
substance (now identified as LTC4 and its metabolites LTD4 and LTE4; Lam and
Austen, 1992) (Huang, 1984).
The observation that antivenoms commonly utilized for the serotherapy of
snakebite show a very limited efficacy in the neutralization of the edema-inducing
activity of venoms (Gutiérrez et al., 1981, 1986e; Lomonte, 1985; Rojas et al., 1987),
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suggests that more efforts should be directed towards its inhibition by combinations of
drugs.
Experimental quantification of edema is usually performed in the paws of mice
or rats, by measurement of simple parameters such as footpad weight, volume,
thickness, or tissue dye accumulation (Yamakawa et al., 1976; Ponton et al., 1983;
Van Loveren et al., 1984; Neves et al., 1993). The biological potency is expressed in
arbitrary units such as the "Minimal Edema-forming Dose" (MED), defined as the
amount of substance that induces 30% edema at a given time. In a comparison of the
potencies of 24 venoms from different families of snakes, MEDs determined at 1 hr
ranged between 0.16 and 3.41 µg/mouse paw (Tan and Saifuddin, 1990).
Snakebite serotheraphy and neutralization of tissue-damaging toxins
Heterologous immunoglobulin preparations with antivenom activity have been
used for the treatment of snakebites since the pioneer work of Calmette, and Phisalix
and Bertrand, in 1894 (reviewed by Grabar, 1986; Ménez, 1991). Industrial
production involves the active immunization of animals, mainly equines, with
sublethal increasing doses of crude venom(s), usually administered with adjuvants.
When antibody levels have reached a predetermined neutralizing titer (against the
lethal effect of the venom), plasma is obtained and processed for the purification of
immunoglobulins. The degree of purification may vary widely among different
producers, ranging from almost no purification (i.e. the use of total plasma as
antivenom), to intermediate (i.e., ammonium sulfate fractionation of globulins,
caprylic acid purification of total IgG), or high (i.e., affinity-purified antibodies)
(Carroll et al., 1992). Some antivenoms are based on undigested antibody molecules,
while others consist of F(ab')2 or Fab fragments (Smith et al., 1992). Antivenoms can
be monovalent, that is, prepared with the venom of a single species, or polyvalent,
prepared with a mixture of venoms from more than one species. In the latter case,
venom mixtures used as immunogens are grouped on the basis of their antigenic
relationships (cross-neutralization characteristics), and geographical distributions of
the relevant snake species in a given country or region of the world (Theakston and
Warrell, 1991).
Not all snakebites require the indiscriminate use of an antivenom, depending on
factors such as species of snake involved and the amount of venom injected.
However, in severe envenomations, especially by some highly poisonous species, the
use of a good quality antivenom is crucial for the clinical outcome (Reid et al., 1963;
23
Russell et al., 1975; Warrell et al., 1980; Reid and Theakston, 1983; Ho et al., 1986b;
Benbassat and Shalev, 1993).
Antivenoms are carefully controlled for their neutralizing potency against the
lethal action of venoms in mice. However, less information is available on their ability
to neutralize other venom actions, among them, the tissue-damaging activities. A
World Health Organization committee stressed the relevance of this point, in
discussing the standardization of antivenoms (W.H.O., 1981). Given the complexity
of venom composition, added to the variability of the immune response in genetically
distinct animals, antivenoms are not expected to contain equal amounts of antibodies
to all venom components, or equal neutralizing potencies against all of them.
Furthermore, with the possible exception of some highly neurotoxic venoms, in which
the main lethal toxins have been identified, the lethal action of the majority of snake
venoms is poorly characterized, as many factors are probably contributing to it in a
synergistic way.
Several studies have been focused on the neutralizing capacity of antivenoms
towards the local tissue-damaging activities of venoms (Homma and Tu, 1970;
Russell et al., 1973; Harris and Johnson, 1978; Gutiérrez et al., 1981, 1985, 1986e,
1987, 1991a; Ownby et al., 1983a, 1984a, 1984b, 1985, 1986; Lomonte, 1985; Rojas
et al., 1987; Ownby and Colberg, 1988; Chaves et al., 1989; Lomonte et al., 1987,
1990d; Mebs et al., 1988; Antunes et al., 1989; Kornalík and Taborska, 1989; Laing
et al., 1992; Dos Santos et al., 1992). In general, experiments have been performed
using two basic modalities, which provide different, but complementary, information
(Gutiérrez et al., 1990a). The first is the preincubation modality, in which an
appropriate amount of the venom (selected on the basis of dose-response analysis) and
varying amounts of the neutralizing agent (antivenom in this case) are mixed,
incubated, and then assayed in vivo for the specific toxic activity. The second
modality consists of the independent administration of venom and antivenom in vivo,
mimicking the actual situation of serotherapy. The first approach may seem irrelevant
from a practical point of view, nevertheless, it provides clear information about the
presence and potency of neutralizing antibodies in the antivenom. The second
approach evaluates the true neutralizing effectiveness of these antibodies with respect
to a specific venom action during in vivo serotherapy, and is influenced by the
pharmacokinetics of both antibodies and venom components, and the speed of toxic
effects. Therefore, a negative result (lack of neutralization) in the independent
administration assay, has two possible explanations: (1) the lack of neutralizing
antibodies in the antivenom; or (2) the ineffectiveness of neutralizing antibodies,
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despite their presence, due to pharmacokinetic considerations. Clearly, the results
provided by the preincubation modality provide the basis to distinguish between these
two alternatives.
In general, experimental evaluations of the neutralizing ability of antivenoms
towards the local tissue-damaging actions of venoms (hemorrhage, myonecrosis, and
edema), have shown only partial inhibitions, even if antivenoms were administered
within the first minutes after the venom. This is in agreement with clinical
observations in which administration of antivenoms seems to have little influence on
the development of local effects (Reid et al., 1963; Warrell et al., 1976b), probably
due to the delay in injection, as time is the most critical factor. One example of this
problem is the hemorrhage induced by the venom of Bothrops asper: the
corresponding antivenom is extremely efficient in neutralizing this effect by
preincubation tests, but hemorrhage is only partially prevented by (early) independent
administration of antivenom in mice (Gutiérrez et al., 1981, 1985). In other cases,
however, it has been clearly shown that antivenoms may lack, or have extremely low
amounts of, neutralizing antibodies against the relevant toxins for a given effect. This
would be the case of a polyvalent antivenom utilized in the United States of America,
which was shown to lack significant amounts of antibodies to myotoxin a and
crotamine (Ownby et al., 1979, 1983b) despite that their immunogenicity was
demonstrated by immunization of rabbits. Another example of a commercially
available antivenom utilized in Latin America, lacking antibodies to the PLA2
myotoxins found in many Bothrops spp. venoms, has been reported (Lomonte et al.,
1991). The reason for this is unclear, since three other antivenoms from different
producers had high antibody titers to these toxins.
Even if the rapid development of tissue damage by venoms is a major obstacle to
the neutralizing efficiency of antivenoms, the aim of obtaining high levels of
neutralizing antibodies against locally-acting toxins should not be neglected. The
partial neutralizations observed at the experimental level obviously imply significant
benefit to the patients. Moreover, the presence of appropriate amounts and
specificities of antibodies in antivenoms should reduce the spreading of toxins (and
damage) to distant sites, as well as their half-lives in the body.
In addition to the conventional neutralization of toxins with antibodies, potential
alternative inhibitors of venom actions, natural or synthetic (Nakagawa et al., 1982;
Mors et al., 1989; Crosland, 1989, 1991; Robeva et al., 1991; Martz, 1992), should be
investigated. A precise understanding of the molecular sites and mechanisms of toxin
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neutralization should help in the design of improved blocking agents for therapeutic
use in the future (Ménez, 1991).
Cytokines in inflammation
When an injurious agent -chemical, physical, or infectious- affects the organism,
a complex response is triggered, involving the participation of many cell types and
their products. Essential to this inflammatory response is the participation of soluble
messengers that allow the proper communication and regulation of the activities of the
different cell types involved. It is now well established that one important group of
mediators produced in response to injurious agents is constituted by the family of
cytokines (Cerami, 1992). Although these molecules are highly pleotropic,
participating in numerous diverse physiological processes, cytokines more typically
involved in inflammatory reactions include IL-1, IL-6, IL-8, TNF-a and IFN-g (Abbas
et al., 1991). The biological activities of these cytokines in relation to inflammation
are briefly summarized below.
Interleukin 1 (IL-1) is produced mainly by mononuclear phagocytes, and occurs
in two forms (a and b), which show low homology, but bind to the same receptor. IL-
1a is mainly found associated to membranes and IL-1b in circulation. In relation to
inflammation, this cytokine can induce the synthesis of enzymes for prostaglandin
production (in turn mediating fever), synthesis of IL-6 and IL-8 by endothelial cells,
and their activation to promote coagulation, expression of adhesion molecules and
leukocyte adhesion (Abbas et al., 1991; Dinarello, 1992). A natural inhibitor for this
cytokine has been described, the IL-1 receptor antagonist (Seckinger et al., 1987; Tilg
et al., 1993).
IL-6 is produced by many cell types, among them macrophages, endothelial
cells, fibroblasts, and T lymphocytes. A known stimulus for its synthesis is IL-1, and
to a lesser extent tumor necrosis factor (TNF-a). Bradykinin has been reported to
induce IL-6 production in fibroblasts (Vandekerckhove et al., 1991). IL-6 does not
cause vascular thrombosis or the tissue injury seen in response to TNF-a. A main
action of IL-6 is the induction of the acute-phase response, together with TNF-a and
IL-1, by affecting the synthesis of several specific proteins in hepatocytes
(Mackiewicz et al., 1988; Castell et al., 1989; Lewis et al., 1992). Histamine can
upregulate IL-6 production and enhances the production of fibrinogen and C3 induced
by IL-6 in the liver (Falus and Merétey, 1992). IL-6 also induces the maturation of
megakaryocytes to increase platelet numbers (Hirano et al., 1990) and stimulates the
division of myoblasts (Austin and Burgess, 1991), among several other actions.
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IL-8 can be produced by all leukocytes, platelets, and endothelial cells, in
response to external stimuli such as lipopolysaccharide, or to other cytokines (IL-1
and TNF-a). It is a chemotactic and activating factor for neutrophils and, to a lesser
extent, for eosinophils, basophils, and lymphocytes (Rot, 1992). A related molecule in
this IL-8 family of peptides, monocyte chemotactic protein-1 (MCP-1) seems specific
for mononuclear phagocytes (Abbas et al., 1991).
TNF-a is mainly produced by macrophages. It stimulates the production of IL-1
and IL-6, and participates in the induction of the acute-phase response, as well as
being responsible for cachexia and shock when high amounts are produced (Sáez-
Llorens and Lagrutta, 1993). An immediate fall in circulating neutrophils, followed by
leukocytosis, lymphopenia, and IL-6 increase, is observed in healthy humans after
TNF-a injection (Dinarello, 1992). TNF-a also induces the expression of adhesion
molecules on endothelial cells (Cramer, 1992), and the synthesis of platelet-activating
factor (PAF), and prostaglandins PGI2 and PGE2 (Dinarello, 1992).
Interferon gamma (IFN-g) is produced mainly by T lymphocytes. Among its
many immunomodulating activities, it is a potent activator of mononuclear
phagocytes, and, to some extent, of neutrophils. It promotes lymphocyte adhesion to
endothelial cells, and potentiates the effects of TNF-a on this cell type (Abbas et al.,
1991).
Several of the cytokines involved in the process of leukocyte migration into
injured tissues are believed to be immobilized and maintained at high concentrations
at or near the vessel wall, probably on endothelial cell surfaces, via the interaction
with their different proteoglycans (Tanaka et al., 1993). Cytokines such as TNF-a, IL-
1, and transforming growth factor beta (TGF-b), increase the synthesis of heparan
sulfate proteoglycan in endothelial cells. This glycosaminoglycan plays a role in the
binding of growth factors for endothelial cells, as well as in maintaining their
permeability barrier function and anticoagulant properties, and is rapidly released
from the endothelial lining of blood vessels during inflammation (Ihrcke et al., 1993).
Despite the known importance of cytokines in the development and regulation of
inflammatory reactions, both acute and chronic, there are no studies available on their
possible involvement in snake venom poisoning.
Heparin and snake venoms
The idea of using heparin in the management of snakebites was proposed almost
50 years ago (Ahuja et al., 1946; Ahuja and Singh, 1954). Since then, a number of
clinical and experimental studies evaluating its possible beneficial effects on the
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severe coagulation disturbances, such as the intravascular coagulation syndrome,
caused by some snake venoms have been reported, with controversial conclusions (De
Vries et al., 1963; Tinoco, 1972; Weiss et al., 1972; Warrell et al., 1976a; Schaeffer
et al., 1986; Shah et al., 1986; Lwin et al., 1989; Than et al., 1989;  Estrade et al.,
1989; Dempfle et al., 1990; Tibballs and Sutherland, 1992; Swe et al., 1992).
Heparin, due to its strongly polyanionic nature, can interact with many
molecules possessing cationic sites (Zhou et al., 1992), and has been used as a tool in
the study of the activities of different kinds of molecules, including snake toxins
(Vaccari and Fregnan, 1955; Condrea and De Vries, 1964; Higginbotham, 1965; Lee
et al., 1970;  Ho et al., 1986b; Melo et al., 1993). Heparin-binding proteins include a
variety of growth factors, proteins of the extracellular matrix, proteins involved in
lipid metabolism, serine protease inhibitors, viral proteins, and enzymes (Zhou et al.,
1992). Among these, the interaction with PLA2s, either affecting their enzymatic
activity (Franson et al., 1974; Diccianni et al., 1990, 1991) or not (Condrea and De
Vries, 1964; Avila and Convit, 1976; Ho et al., 1986a; Horigome et al., 1987), is of
interest in snake venom research, as these enzymes possess several
pharmacological/toxic actions, as discussed above (Rosenberg, 1990).
It has been reported that heparin can neutralize the myotoxic activity of the
venom of Bothrops jararacussu (Melo and Suarez-Kurtz, 1988) or, very recently, one
of its myotoxic components, bothropstoxin, of the group of non-neurotoxic PLA2s
(Melo et al., 1993). These findings suggest that, apart from its still debated effects on
the coagulation disturbances caused by some venoms, heparin might have an
additional usefulness in the treatment of snakebites, as a direct neutralizing molecule
for particular venom components.
Heparin is a glycosaminoglycan mainly composed of repeating units of
hexuronic acid (either iduronic acid or glucuronic acid) and glucosamine, carrying a
high number of sulfate substitutions, which are responsible for its strong negative
charge. Sulfate groups may be found in five different locations: linked to the amino
groups of the glucosamine moiety (N-sulfate), and as ester sulfate (O-sulfate) on C-6
and C-3 of glucosamine, and on C-2 of iduronic and glucuronic acid (Rodén et al.,
1992). Owing to the variability in sulfate substitution, heparin, like other
glycosaminoglycans, displays considerable sequence heterogeneity both within and
between different chains (Kjellén and Lindahl, 1991). Heparin is polydisperse, with a
molecular weight ranging from 5 to 40 kD, and an average of 13-15 kD (Linhardt et
al., 1992). Only about one third of the molecules of standard heparin preparations
contain the specific pentasaccharide sequence required to interact with antithrombin
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and exert anticoagulant activity (Rodén et al., 1992). Thus, it is possible to fractionate
heparin by affinity chromatography on immobilized antithrombin, in order to obtain
preparations with very low or no anticoagulant action ("low affinity" heparin), and
full anticoagulant action, respectively.
Heparin is produced only by mast cells, being found in their secretory granules.
Virtually all other cell types synthesize heparan sulfates, which show similar
fundamental compositions and structures to heparins, but also substantial quantitative
differences. There is more glucuronic acid and, consequently, less iduronic acid in
heparan sulfate than in heparin, the N-acetyl content is higher and the N-sulfate
content lower, and the degree of O-sulfation is lower (Rodén et al., 1992). These
characteristics give heparan sulfate a lower overall charge density in comparison to
heparin, although clusters of N-sulfated, more extensively modified, sequences, are
still present in the former (Kjellén and Lindahl, 1991).
AIMS OF THE STUDY
1.To characterize the local tissue damage and inflammatory reactions that develop
after experimental injection of snake venoms and isolated toxins, in a mouse model.
2.To develop and evaluate experimental in vivo and in vitro methods to quantify cell
and tissue damage caused by venoms and toxins, as well as their neutralization by
antibodies or drugs.
3.To characterize the ability of heparins to interact with, and neutralize, myotoxins
from snake venoms.
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MATERIALS AND METHODS
Snake venoms
The venoms of Bothrops asper (Pacific variety) and Micrurus nigrocinctus
nigrocinctus were pools obtained from at least 30 specimens of each species,
collected in Costa Rica, and kept at the serpentarium of Instituto Clodomiro Picado
(University of Costa Rica). Immediately after collection, venoms were centrifuged
to remove debris, lyophilized, and stored at -20°C. The venoms of Vipera berus
(Russian origin), Agkistrodon piscivorus piscivorus, Bothrops jararacussu, Crotalus
durissus terrificus, Crotalus viridis viridis, Naja naja atra, and Trimeresurus
flavoviridis (unspecified geographical origins) were obtained from Sigma Chemical
Co. (St. Louis, MO, U.S.A).
Purified toxins and synthetic peptide
Myotoxin II was purified from the venom of B. asper by two cycles of ion-
exchange chromatography on CM-Sephadex C-25 (Pharmacia, Sweden) as
described by Lomonte and Gutiérrez (1989). Myotoxin III (Kaiser et al., 1990) and
hemorrhagic metalloproteinase BaH-1 (Borkow et al., 1993) purified from the same
venom, were kindly provided by Dr. J.M. Gutiérrez (University of Costa Rica).
A 26-mer peptide corresponding to the amino-terminal sequence of myotoxin
II (Ser-Leu-Phe-Glu-Leu-Gly-Lys-Met-Ile-Leu-Gln-Glu-Thr-Gly-Lys-Asn-Pro-Ala-
Lys-Ser-Tyr-Gly-Ala-Tyr-Gly-Cys) with native endings was synthesized by Chiron
Mimotopes Ltd. (Victoria, Australia) using Fmoc strategy (Valerio et al., 1993) and
had an estimated purity of 96% by HPLC on a LiCrosphere 100RP-18 column. The
amino acid sequence was based on data from Francis et al. (1991).
Antivenoms and other antibodies
Equine polyvalent crotalid antivenom (batches P-183 and 203LQ) and anti-
Micrurus nigrocinctus antivenom (batch 207A89LF) for human use were prepared
at the Instituto Clodomiro Picado (University of Costa Rica), as described by
Bolaños and Cerdas (1980).
A rabbit antiserum against Vipera berus venom was raised by injecting 1 mg
of venom, emulsified with Freund's complete adjuvant, by the i.m. route. On days
21, 36, and 51, respectively, additional 1 mg doses were given using sodium
alginate as a vehicle. Serum was obtained 14 days after the last booster
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immunization. The antibody titer and reactivities were determined by enzyme-
immunoassay and immunoblotting, respectively, as described below.
MAb-3, a mouse IgG1 neutralizing monoclonal antibody against B. asper
myotoxins (Lomonte and Kahan, 1988) was prepared as ascitic fluid in pristane-
primed BALB/c mice, and partially purified by ammonium sulfate precipitation. Its
concentration was determined by radial immunodiffusion (Mancini et al., 1965)
using a mouse IgG1 standard (Sigma).
Heparins and other glycosaminoglycans
Standard heparin (5000 IE/ml), heparin with low affinity for antithrombin
(LA-heparin; 7 IU anti-factor Xa/mg, Mr 15 kD), and low molecular weight heparin
(Fragminâ, 25000 IE/ml, Mr 5 kD) were kindly provided by Kabi Pharmacia
(Sweden). Heparan sulfate (from bovine intestinal mucosa, H-7641) and a series of
heparin-derived disaccharides were obtained from Sigma. A low-sulfated heparan
sulfate preparation (~0.6 sulfate group/disaccharide unit) from human aorta (Iverius,
1971) was kindly provided by Dr. W. Murphy (University of Monash, Australia).
Chondroitin sulfate (from bovine cartilage) and dermatan sulfate (from pig intestinal
mucosa) were prepared as described by Lycke et al. (1991). Heparin from pig
intestinal mucosa (Lindahl et al., 1965) was radiolabeled by [3H]acetylating free
amino groups with labeled acetic anhydride (Höök et al., 1982). Even-numbered
heparin oligosaccharides were generated by partial deaminative cleavage with
nitrous acid (pH 1.5; Shively and Conrad, 1976; Pejler et al., 1988), followed by
reduction with NaB3H4 (Amersham, U.K.). Labeled oligosaccharides were
separated by repeated gel filtration on Sephadex G-50 into even-numbered species,
from 4- to 14-saccharides (Lane et al., 1984). Selectively O-desulfated heparins (2-
O-desulfated and 6-O-desulfated) were kindly given by Drs. A. Naggi and G.
Grazioli (Istituto G. Ronzoni, Milano, Italy). N, O-desulfated heparin was prepared
as described by Nagasawa et al. (1977). This preparation was subjected to either
complete re-N-sulfation (Lloyd et al., 1971) or complete re-N-acetylation
(Danishefsky et al., 1965).
Venom lethal activity
Lethal potency was determined in Swiss mice (16-18 g) using groups of five
animals per dose (i.p., in 500 ml of phosphate-buffered saline; PBS). Deaths were
scored after 48 hr, and the lethal dose 50% (LD50) was calculated by probit
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analysis using the computer program described by Trevors (1986). Animal
experiments were performed in accordance with ethics permit #53-92.
Hemorrhagic activity
 Hemorrhage induced by venoms or toxins was quantified in mice (18-22 g), 2
hr after i.d. injection (in 100 ml of PBS), by measuring the diameter of the
hemorrhagic spot formed in the internal side of the skin (Kondo et al., 1960).
Edema-forming activity
Edema was quantified in the footpad of mice (22-28 g) by measuring the
thickness increase with a low-pressure spring caliper (Oditest, H.C. Kröplin,
Germany) (Van Loveren et al., 1984). Venoms or toxins were injected s.c. in a total
volume of 50 µl of PBS.
Myotoxic activity: plasma creatine kinase method
Venoms or toxins were injected i.m. into mice (gastrocnemius muscle) in a
volume of 50-100 µl of PBS. Control animals received PBS alone. After 3 hr
(Gutiérrez et al., 1984a, 1991a), serum levels of creatine kinase (CK; EC 2.7.3.2)
were determined by a colorimetric assay (Sigma No.520). Activity was expressed as
units/ml, one unit being defined as the phosphorylation of one nanomole of creatine
per min at 25°C.
Myotoxic activity: muscle residual creatine kinase method
Mice injected i.m. (as above) were sacrificed after 24 hr, and both
gastrocnemius muscles (injected and contralateral control) were removed, weighed
and homogenized in 4 ml of PBS containing 1% Triton X-100, using a Brinkmann
PT10/35 homogenizer (Polytron, Switzerland). After centrifugation at 1000 g for 10
min, each supernatant was diluted 1:40 with distilled water and 7 µl of this dilution
were assayed for CK activity (as above). The activity of each supernatant was
divided by its corresponding muscle weight. The muscle residual CK activity was
expressed as a percentage of the corresponding control (contralateral) muscle value.
Myotoxic activity: muscle residual MTT-reduction method
Muscle homogenates were prepared exactly as above, from mice injected i.m.
in the gastrocnemius. Then, 1 ml of each supernatant (undiluted) was mixed with
0.2 ml of MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide)
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solution (2.5 mg/ml PBS) in a 1.5 ml microfuge vial and incubated in the dark at 37°
C for 90 min. Final absorbances were determined at 570 nm against a 690 nm
reference (Denizot and Lang, 1986) on a Shimadzu UV-160 spectrophotometer.
Each absorbance value was divided by its corresponding muscle weight. The muscle
residual MTT-reducing activity was expressed as a percentage of the control
(contralateral) muscle value.
Myotoxic activity: quantitative histological method
Venom was injected by i.m. route as above. After 24 hr, the injected
gastrocnemius muscle was removed, cut transversally in the middle portion, and
immediately immersed in Duboscq-Brasil fixative (10% formalin, 50% ethanol,
6.5% acetic acid, 0.45% picric acid), then dehydrated in ethanol and embedded in
paraffin. The orientation of the tissue was carefully controlled during embedding in
order to obtain cross sections. Transverse sections (5-8 mm) were stained with a
modified Masson trichrome stain (Arce, 1986). Video recordings encompassing the
whole area of each section were made, and the total number of necrotic and normal
muscle cells were counted for each sample. A "Necrosis Index" was calculated as
number of necrotic cells/total number of cells.
For qualitative histological evaluations, tissue samples were fixed in 4%
paraformaldehyde, 0.1 M cacodylate buffer (pH 7.4), decalcified (if pertinent),
embedded in parafin, and stained with hematoxylin-eosin.
Intravital microscopy
Local tissue damage induced by B. asper venom or myotoxin II was analyzed
by intravital microscopy. Male C57BL mice (ALAB, Sweden) were anaesthetized
and placed in supine position on a water-heated bed. The cremaster muscle was
surgically exposed, pinned onto a special heated observation platform, and covered
with a thin Mylar® sheet (6 mm) to prevent evaporation. Tissue reactions were
observed in a Leitz vital microscope, equipped with a color TV-camera (WV
CD130; Panasonic, Japan), a black and white low light-level TV-camera for
fluorescence microscopy (WV-1900/G; Panasonic), a VCR (NV-FS88 HQ;
Panasonic), a video timer (VTG-33; FOR-A Co. Ltd, Japan), a 19" video color
monitor (Panasonic), a VCR image enhancer (Detailer II; Vidicraft, Japan), and a
video copy processor (P66E, Mitsubishi, Japan). Dry objectives x2.5;0.08, x6;0.18,
x20;0.32 and water immersion objectives x55;084 and x75;1.0 were used in
combination with x12.5 eye-pieces. A Leitz Ploemopak illuminator and a Xenon
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burner (150 W) were used for incident light fluorescence microscopy to study
microvascular plasma leakage. This was visualized by i.v. injection of 0.10-0.15 ml
of FITC-dextran (25 mg/ml PBS; mol wt 147,800; Sigma) given 5 min before the
local application of venom or myotoxin, through the cannulated left femoral vein.
For studies on plasma leakage, venom or myotoxin were mixed with 1% agarose-
saline at 50°C, and immediately 20 ml (of 2.5 mg/ml final concentration) were
spread over a small piece of plastic film (GelbondÒ, Pharmacia). The gel was
gently placed on the tissue after moving the MylarÒ to the side so that it covered
about 2/3 of the muscle, serving as a control area. After 5 min exposure to the gel,
the muscle was flushed with warm saline and covered again. The transparency of
the gel allowed continuous observation of the microcirculation during the period
that it was in contact with the muscle. For the rest of the experiments, the whole of
the muscle was exposed to venom or myotoxin by lifting off the MylarÒ and
dripping 20 ml of a solution of either substance (2 mg/ml) on the tissue. The
exposure time varied from 5-30 min, during which the muscle was covered, before
being flushed with warm saline and once again covered for the following
observation period (30 min).
Electron microscopy
At the end of some of the intravital microscopy experiments, the cremaster
muscle was fixed for 5 min with a solution consisting of 2.5% glutaraldehyde, 1%
paraformaldehyde and 0.01% sodium azide in 0.05 M sodium cacodylate, pH 7.2,
and then removed. The specimens were further fixed in the same solution overnight,
followed by post-fixation in 1% OsO4 in 0.1 M sodium cacodylate, dehydration and
infiltration with epoxy resin (Agar 100) according to routine procedures. Ultrathin
sections were cut with diamond knives in a Reichert Ultracut E microtome and
contrasted with lead citrate and uranyl acetate before examination in a Zeiss CEM
902 electron microscope.
Quantification of cytokines
The release of proinflammatory cytokines, after the injection of venoms or
toxins into mice, or after the in vitro exposure of their splenic cells to venoms, was
evaluated by either immunoassay or bioassay.
TNF-a was quantified by cytotoxicity on the WEHI 164-clone 13 murine
fibrosarcoma cell line (Espevik et al., 1986). Cells were cultured in the presence of
test samples (sera or culture supernatants) or recombinant murine TNF-a standards
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(Genzyme, Cambridge, MA) ranging from 0.06 to 1000 pg/ml. After 20 hr, 10
µl/well of a 5 mg/ml solution of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-
tetrazolium bromide (MTT) were added for 4 hr. Then, the medium was decanted
and the formazan product was dissolved with 100 ml/well of 95% ethanol for 10
min, with constant shaking. Absorbance was read at 578 nm on a Titertek Multiskan
(Flow Laboratories, Finland). The lower detection limit was 0.1 pg/ml.
IL-6 was quantified by a proliferation assay using the murine B-cell
hybridoma line B9 (Nelle et al., 1988). Cells were cultured in the presence of test
samples (sera or culture supernatants) or recombinant murine IL-6 standards (AMS
Biotechnology, Sweden) ranging from 0.12 to 8 pg/ml, during 72 hr. Then, 1
µCi/well of 3H-thymidine (Amersham, UK) was added, and after 4 hr cells were
harvested and thymidine incorporation was measured on a direct b-counter (Inotech,
Switzerland).
IL-1a was quantified by a monoclonal antibody-based enzyme-immunoassay
(Intertest 1a-X, Genzyme, Cambridge, MA) according to the manufacturer's
instructions. The lower detection limit of the assay was 15 pg/ml.
Mitogenicity
The possible mitogenic action of B. asper venom on mouse lymphocytes was
assessed by culturing spleen cells (4x105 cells/well; Bradley, 1980) in the presence
of different venom concentrations, during 72 hr. Venom was sterilized by filtration
through 0.22 mm membrane. As a positive control, Escherichia coli B 055:B5
lipopolysaccharide (10 mg/ml; Difco, Detroit, MI) was included. Cell proliferation
was quantified by incorporation of  3H-thymidine during 4 hr.
Cytotoxicity on mouse spleen cells
B. asper venom was added, in different concentrations, to spleen cells in 24-
well plates (2x106 cells/well). After 6, 24, 48, and 72 hr, cells were harvested
manually and the viability was estimated by an automated cell counter (Sysmex F-
300, Toa Medical Electronics, Japan), in comparison to control wells in which
venom was omitted.
Hematological alterations in vivo
B. asper venom (50 mg) was injected s.c. into the footpad of mice and at 0, 1,
3, 6, 12, 24, 72 hr, and 7 days, heparinized (200 U/ml) blood samples were obtained
under anesthesia. White blood cells and platelets were counted in a Sysmex K-1000
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analyzer (Toa Medical Electronics). Differential counts for leukocytes were
performed on Giemsa-stained blood smears.
In vivo complement depletion
To assess the possible role of complement in the development of edema and
IL-6 induction, Swiss mice were treated with an i.p. injection of "cobra venom
factor" (Sigma) at a dose of 0.8 µg/g body weight, 16-18 hr before the respective
experiments (Vogel, 1991). Control mice were treated with PBS. Complement
depletion was verified by measuring serum C3 levels by radial immunodiffusion
(Mancini et al., 1965), using a goat antiserum to mouse C3 (Cappel, North Carolina,
U.S.A.) at a final concentration of 1% (v/v) in the agarose gel, and serum samples of
5 µl. The reduction in C3 levels obtained with this treatment was 91-93%.
Cytotoxicity on skeletal muscle myoblasts (L6) and endothelial cells (tEnd)
An in vitro quantitative assay for the cytotoxic activity of purified toxins was
developed, using two cell lines: L6 rat skeletal muscle myoblasts (ATCC CRL
1458), and tEnd cells, a polyoma virus-transformed murine endothelial cell line of
capillary origin (Bussolino et al., 1991), kindly provided by Dr M. Thelestam
(Karolinska Institute, Sweden) and Dr A. Mantovani (Istituto di Ricerche
Farmacologiche Mario Negri, Italy), respectively. Cells were routinely grown in
Iscove's medium (Gibco, Paisley, UK) supplemented with 10% fetal calf serum
(FCS; Biological Ind., Haemek, Israel), 2 mM L-glutamine, 5x10-5 M 2-
mercaptoethanol, and 0.05 mg/mL gentamycin. In order to quantify cytotoxicity,
cells were seeded in 96-well plates and grown for 2-4 days until near confluence. At
the moment of the assay, culture medium was removed and replaced with 150
µl/well of medium with 1% FCS containing different amounts of toxins. The FCS
concentration was lowered to 1% in order to minimize the basal lactate
dehydrogenase (LDH; EC 1.1.1.27) activity of the medium. After 3 hr of incubation
at 37°C (selected after time-course experiments), 100 µl of supernatant were
assayed for LDH released from damaged cells (kit No.500, Sigma). As reference
values for 100% and 0% cytotoxicity, cells were incubated with 0.1% Triton X-100-
containing medium, or plain medium, respectively.
Cell surface heparan sulfate treatments
The possible role of cell surface heparan sulfate in the cytotoxic mechanism of
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myotoxin II was investigated by (a) heparitinase digestion of cell cultures, (b)
inhibition of heparan sulfate sulfation with sodium chlorate, and (c) the use of a cell
mutant with a defect in heparan sulfate biosynthesis.
For heparitinase treatment, cell cultures were incubated with 1.25 U/well of
heparinase III (Sigma), in 100 µl of PBS, for 2 hr at 37°C (WuDunn and Spear,
1989). Control cells were treated similarly but omitting the enzyme. Then, wells
were washed twice with culture medium, and the cytotoxicity induced by myotoxin
II was determined by LDH release. For chlorate treatment, cells were plated in
microwells with medium containing 10 mM sodium chlorate (Greve et al., 1988;
Olwin and Rapraeger, 1992) and grown for 2 days. At the moment of the assay,
myotoxin II was added in chlorate-containing medium, and cytotoxicity was
determined. Chlorate was omitted in control cultures. Finally, the cytotoxic action
of myotoxin II was also quantified on two CHO cell lines, one defective in the
synthesis of heparan sulfate (CHO-pgsD-677), and the wild type control (CHO-K1)
(Lidholt et al., 1992), kindly provided by Dr. J.D. Esko (University of Alabama-
Birmingham, U.S.A.).
Proteolytic and phospholipase A2 activities
Proteolytic activity was tested by incubation of varying amounts of venom
with 1% casein in PBS for 30 min at 37°C. Proteins were then precipitated by
addition of trichloroacetic acid, and the increase of absorbance at 280 nm of the
supernatants was determined (Lomonte and Gutiérrez, 1983). Phospholipase A2
(PLA2) activity of venoms or toxins was estimated by an indirect hemolytic assay in
the presence of egg yolk phospholipids (Gutiérrez et al., 1988), either in gel or in
fluid phase.
Fibrinolytic, coagulant, and anticoagulant activities
 Fibrinolytic activity of venoms was determined on equine fibrin clots using the
radial diffusion assay described by Gené et al. (1989). Coagulant activity was tested
on human plasma at 37°C, by measuring the time to clot formation after adding
varying amounts of venom, as described by Gené et al., (1989). Anticoagulant
activity was determined as described by Alvarado and Gutiérrez (1988), by
preincubating venom with platelet-poor human plasma at 37°C for 10 min, and then
adding CaCl2 to initiate coagulation.
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Electrophoretic analyses and densitometry
Venoms, fractions, or purified toxins were analyzed by sodium dodecylsulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), with or without reduction with 2-
mercaptoethanol, on homogeneous 12 or 15% gels (Laemmli, 1970). Basic proteins
were analyzed also by native cathodic PAGE on 12 or 15% gels (Reisfeld et al.,
1962). All electrophoreses were run in a Mini-Protean cell (Bio-Rad, Richmond,
CA, U.S.A.). Proteins were stained with Coomassie blue R-250 and, when
pertinent, the gels were scanned on a GS300 Densitometer  and analyzed with the
GS365W Electrophoresis Data System (Hoefer Instruments, San Francisco, CA,
U.S.A.) to determine the molecular weight and relative concentrations of the
components.
Immunoblotting
Reactivity of the rabbit anti-V. berus serum towards the different venom
components was tested by immunoblotting. Unreduced venom was separated by
SDS-PAGE and transferred to nitrocellulose in a Mini-Transblot cell (Bio-Rad)
(Towbin et al., 1979). Proteins on the nitrocellulose were reversibly-stained with
amidoblack 10B (Syu and Kahan, 1987) to check for transfer efficiency. Strips were
cut, blocked with bovine serum albumin and casein, and then incubated with either
immune or normal rabbit sera. Bound antibodies were detected with an alkaline
phosphatase anti-rabbit IgG conjugate, using nitroblue tetrazolium and 5-bromo-4-
Cl-3-indolyl phosphate (Sigma) as substrates.
Gel diffusion
The interaction between heparins and B. asper venom or myotoxin II was
tested by gel diffusion in 1% agarose-PBS plates (Ouchterlony and Nilsson, 1978).
After 24 hr of incubation at room temperature, gels were washed with PBS and the
precipitates stained with Coomassie blue R-250.
Enzyme-immunoassay
Detection of polyclonal and monoclonal antibodies to venoms or toxins was
performed by direct enzyme-immunoassay on antigen-coated plates. After addition
of samples, bound antibodies were detected by appropriate anti-Ig-enzyme
conjugates (either with peroxidase or alkaline phosphatase) and subsequent color
development, as previously described (Lomonte et al., 1991; Rovira et al., 1992).
Normal sera from the same species was always used as a negative control.
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A competitive enzyme-immunoassay was utilized to determine if heparin
could inhibit the binding of MAb-3 (a neutralizing monoclonal antibody) to
myotoxin II. Binding competition was assessed both by incubating a fixed amount
of heparin with varying amounts of MAb-3, or a fixed amount of MAb-3 with
varying amounts of heparin. Horse polyvalent antivenom was utilized as a positive
control for competition in the binding of MAb-3 to myotoxin II.
Heparin-affinity chromatography
B. asper venom was fractionated on a column of heparin-agarose (Sigma)
equilibrated with PBS, pH 7.2, in order to obtain the heparin-binding components.
After the absorbance at 280 nm of the eluent returned to baseline, elution of the
bound material was performed by either a stepwise or a linear gradient to 1 M NaCl.
The salt-eluted fraction was then analyzed by SDS-PAGE and native cathodic
PAGE as described above.
Heparin binding assay
A quantitative filter binding method (Maccarana et al., 1993), was utilized to
study the interaction of myotoxin II with heparin, its derivatives, fragments, and
other glycosaminoglycans (GAGs). The toxin was incubated at room temperature
for 2 hr with the appropriate 3H-labeled saccharide samples in 300 µl of 50 mM
Tris-HCl, pH 7.4, 130 mM NaCl (TBS) containing 0.5 mg/ml of bovine serum
albumin. The protein, along with any bound carbohydrate, was recovered by quick
passage of the mixtures through nitrocellulose filters (Sartorius, pore size 0.45 µm;
25 mm diameter) which had been placed onto a 10-well vacuum-assisted manifold
filtration apparatus. The filters were prewashed twice with 5 ml of TBS, before
application of the samples, which were immediately followed by another two
washings with the same buffer; each washing step was completed within 5 sec.
Protein-bound radioactivity was determined after submersion of the filters in 2 ml of
2 M NaCl for 30 min; 1.5 ml of the eluate was mixed with 1 ml of distilled water
and 8 ml of scintillation cocktail (OptiPhase, Pharmacia LKB Biotechnology,
Sweden) and counted in a Beckman LS 6000IC scintillation spectrometer. No
residual radioactivity could be detected on the filters.
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RESULTS
Inflammatory response to Bothrops asper snake venom (paper I)
B. asper venom induced a potent inflammatory response in the mouse when
injected s.c. in the footpad. Both local and systemic alterations were observed.
Locally, a striking immediate edema was elicited, which lasted from 12 hr to more
than three days, depending on the dose injected. The edema could be induced in the
absence of a hemorrhagic effect, although bleedings were associated with a more
prolonged edema. A diffuse inflammatory infiltrate accumulated by 6 hr in the
injected footpad, both in the subcutaneous and muscular tissues (showing
hemorrhage and myonecrosis), predominantly consisting of polymorphonuclear
neutrophils. At 24 and 72 hr the cellular infiltrate increased and mononuclear
phagocytes appeared, in addition to the neutrophils. After one week the infiltrate had
almost completely disappeared, except for some fibrotic foci still containing
macrophages.
Systemically, significant hematological alterations were induced by the venom.
Platelets decreased almost immediately and did not normalize until 12 hr after
venom injection. A moderate leukocytosis and lymphopenia was observed, with a
rapid inversion of the ratio between these two cell types during the first 6 hr, which
returned to normal by 24 hr.
A rapid elevation of serum IL-6 levels was induced by the venom, peaking at 3-
6 hr and returning to normal by 12 hr. No elevations of TNF-a and IL-1a could be
detected in serum after venom injection. This was not due to the detection systems,
since control animals injected with E. coli LPS had high serum levels of both
cytokines. Additional control tests indicated that the venom, at the concentrations
utilized, did not interfere with the indicator systems for cytokine quantification,
neither changed the activity of recombinant cytokines after their preincubation.
The systemic IL-6 response was obtained also after s.c. injection of purified
myotoxin II, or of whole venom previously incubated with an amount of antivenom
that completely neutralized its hemorrhagic activity (paper I). Additional studies
showed that a high IL-6 response could be similarly induced by two other venoms
tested (Vipera berus and Crotalus viridis viridis) and, as well, by the purified
hemorrhagic toxin BaH-1 from B. asper venom (Table 2).
IL-6 production could not be induced by directly incubating the venom with
mouse spleen cell suspensions in vitro, while a moderate dose-dependent cytotoxic
action was detected. The venom was not mitogenic for splenocytes either.
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An experiment performed to explore the possible involvement of endothelial
cells in the production of IL-6 in response to venom or myotoxin II showed a slight,
but significant (p<0.01), increment of IL-6 released to the supernatant, at 9 and 24 hr
(Fig.1). The i.v. injection of human recombinant IL-6 (100 ng) into mice, 6 hr before
the i.d. injection of B. asper venom, did not result in a significant decrease of the
hemorrhagic effect in comparison to untreated controls (Table 3). In addition,
preincubation of B. asper venom with human a2-macroglobulin (a2M), at a ratio of
50 µg venom/mg a2M, did not reduce its hemorrhagic activity in mice (p>0.05,
n=4).
Table 2: Serum IL-6 induction 3 hr after the s.c. footpad injection
of snake venoms or hemorrhagic toxin BaH-1, in mice.
____________________________________________________
Substance Dose   n IL-6 concentration
         (pg/ml)*
____________________________________________________
Vipera berus venom 50 µg   4 2374 ± 825
Crotalus viridis viridis venom 50 µg   3 5205 ± 1215
BaH-1 hemorrhagic toxin   5 µg   3 1684 ± 384
____________________________________________________
*Serum IL-6 levels in normal mice were < 20 pg/ml.
Table 3: Effect of the preinjection of recombinant
human IL-6 on the hemorrhagic activity of Bothrops
asper venom, in mice*.
_____________________________________________
Group n    Hemorrhagic area (mm2)
_____________________________________________
Control 5 83 ± 29
rhIL-6 treated 5 65 ± 27     N.S.
_____________________________________________
*Control mice were left untreated, while the
experimental group received 100 ng of recombinant
human IL-6 i.v., 6 hr before the assay of hemorrhage
induced by 10 µg of venom administered i.d. N.S.: non
significant difference (p>0.05).
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Figure 1: IL-6 release from endothelial cells (tEnd) cultured in the
presence of medium only (control), B. asper venom (0.1 µg/ml), or
myotoxin II (5 µg/ml). Each bar represents mean ± SD of four
independent cultures, each supernatant assayed in triplicate. The asterisks
indicate a statistically significant (p<0.01) difference of the values in
comparison to the control values at the same time point.
The possible involvement of complement in the mechanism of induction of the
IL-6 response and edema by B. asper myotoxin II, was explored by pretreating mice
with "cobra venom factor". This treatment resulted in a 91-93% reduction of serum
C3. As shown in Fig.2, no difference with the control group could be observed in the
complement-depleted mice regarding footpad edema. Similarly, complement
depletion did not modify significantly the IL-6 response elicited by i.m. myotoxin II
injection (Table 4).
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Figure 2: In vivo complement depletion by "cobra venom factor" (CVF)
pretreatment does not affect the footpad edema induced by myotoxin II in
mice. CVF (or PBS for the control group) was given i.p. (0.8 µg/g body
weight) 18 hr before toxin injection (100 µg). Each point represents
mean ± SD of four mice.
Table 4: Serum IL-6 response elicited by i.m. injection of B. asper
myotoxin II in mice pretreated with "cobra venom factor (CVF)"*.
_____________________________________________________
Group n Serum IL-6 (pg/ml)
_________________________________ ____________________
(1) Myotoxin II 3 1510 ± 240
(2) CVF + Myotoxin II 3 1711 ± 450
(3) CVF only 3   138 ± 46
_____________________________________________________
*CVF i.p. treatment was 0.8 µg/g body weight, 18 hr before the i.m.
injection of myotoxin II [100 µg, (1) and (2)], or PBS (3). IL-6 was
measured 3 hr after toxin injection. The difference between (1) and (2)
is not significant, while group (3) is moderately increased in
comparison to normal levels (<20 pg/ml).
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Characterization of the venom of Vipera berus (paper II)
V. berus venom was highly lethal to mice (i.p. LD50 of 0.86 ± 0.15 µg/g body
weight) and induced significant local tissue damage characterized by marked
hemorrhagic and edema-forming effects, and a moderate myotoxicity, in the mouse.
The footpad edema was rapid, drastic, and its duration was related to the dose
injected. The minimum hemorrhagic dose obtained was 3.2 µg. Local myotoxic
activity was demonstrated by histological evaluation 24 hr after i.m. injection, and
by the dose-dependent creatine kinase release to plasma, measured at 3 hr, or by the
decreased muscle MTT-reducing activity measured at 24 hr. In vitro, this venom had
a moderate proteolytic activity on casein (59.2 U/mg) and displayed PLA2 activity,
detectable by an indirect hemolytic assay in gel with 0.3 µg venom/well or higher
amounts. Fibrinolytic and anticoagulant activities were low, and there was no
coagulant effect on human plasma.
An antiserum to V. berus venom showed significant cross-reactivities to several
crotalid venoms by enzyme-immunoassay, ranging from 62% for Bothrops asper to
18% with Crotalus durissus durissus. V. berus venom was resolved into 10-11
protein bands when electrophoretically separated on the basis of size by SDS-PAGE.
All the bands were recognized by the rabbit antiserum in immunoblots from
unreduced SDS-PAGE separations.
New method for quantification of myonecrosis (paper III)
The venom of Micrurus nigrocinctus was utilized in the development of a
method for the estimation of myonecrosis in mice, and evaluation of the neutralizing
ability of antibodies. Normal muscle (gastrocnemius) homogenates prepared in the
presence of 1% Triton X-100 were found to contain MTT-reducing activity. The
purple formazan product remained in solution, eliminating the need for further
solubilization procedures. The muscle MTT-reducing activity decreased rapidly after
venom injection, reaching a plateau at about 20% residual activity after 24 hr. This
time point was selected for all subsequent experiments. The evaluation of dose-
response curves for venom-induced myonecrosis, in the range of 0.6-20 µg/muscle,
showed that the residual MTT-reducing activity correlated well with the number of
viable cells in the tissue, as determined by quantitative histological evaluation. This
correlation was better than that observed when measuring the residual CK activity of
the muscle, which overestimated myonecrosis in comparison to the histological
evaluation.
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In plasma, a dose-dependent increase in CK levels was observed at 3 hr, over
the whole range tested, still increasing at doses which had destroyed virtually all
muscle fibers in the injected gastrocnemius, as determined by the histological
reference technique.
The use of the MTT-based technique in asessing the neutralization of myotoxic
activity of M. nigrocinctus venom by an antivenom was evaluated. The method
indicated a complete inhibition of venom myotoxins at an antivenom/venom ratio of
4 ml/mg or higher, with a 50% effective dose (ED50) of approximately 2.5 ml/mg.
Dynamics of the local tissue damage induced by Bothrops asper venom (paper IV)
The acute tissue damaging effects of B. asper snake venom and myotoxin II on
the mouse cremaster muscle, were studied by intravital and electron microscopy.
Muscle fibre contractions appeared between 10 and 60 sec after contact between
venom and tissue, and caused a pronounced mechanical distortion of the
microvasculature. At the same time, sphincter-like arteriolar constrictions were
observed, causing intermittent reduction in the blood flow in the depending capillary
networks for about 1 min. Both muscle contractions and arteriolar constrictions
ceased within 2 min, and did not reappear even when the muscle was exposed to
venom for up to 30 min. Another early event, occurring within 1 min and continuing
during the whole observation period, was the formation of thrombi in the
postcapillary venules, giving rise to numerous emboli, and an accumulation of
leukocytes along the venular endothelium.
Leakage of i.v. injected FITC-dextran started about 2 min after venom
exposure, and seemed to originate mainly from small venules and their adjoining
capillary segments. About 5-6 min after the application of the venom, a large
proportion of the observed area showed diffuse leakage. Stasis in the
microcirculation, with a dense packing of erythrocytes in capillaries and small
venules occurred at about the same time as the plasma leakage.
Microbleedings regularly appeared after about 4-6 min of exposure and were
always explosive in character. They originated from capillaries and small venules,
and often developed as a series of burst-like enlargements of the microhematoma
before stopping within about 10-20 sec. In many cases the blood flow through a
ruptured microvessel continued after the bleeding had stopped. No bleedings
originated from arterioles. Electron microscopy (EM) revealed that seemingly intact
and ruptured microvessels could be found adjacent to each other in a damaged tissue
area. Furthermore, the EM showed that erythrocytes escaped through gaps in the
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endothelial wall, with indications that some cellular component was fragmented at
that site. Another striking phenomenon in the microcirculation, noted both
intravitally and by EM, was the accumulation of spherical, but apparently not
hemolysed, erythrocytes.
 As dramatic in appearance as the bleedings, but often starting already after
about 3-4 min, was the degeneration of muscle fibers. The process started as a focal
loss of striation seen as a narrow band across the entire width of the fiber, followed
by the appearance of a small, wedge-shaped lesion at one edge of the fiber and a
slow retraction of the myofibrils in opposite directions, which widened the gap until
the fiber suddenly ruptured. This rupturing was often repeated along the same fiber
so that in the end there was only a row of  fragments separated by spaces, apparently
devoid of myofibrillar material. Despite this severe morphological alteration of the
tissue, there was still blood flow in apparently undamaged microvessels running
along and across the affected muscle fibers.
Application of myotoxin II to the cremaster resulted in a similar, rapid reaction
as with venom, i.e. there were muscle contractions and a concomitant distortion of
the microvasculature, but there were no arteriolar constrictions. The microvascular
permeability also increased, although to a lesser extent than with whole venom. No
thrombi, emboli or bleedings were observed during the experiments. The main
lasting effect was the drastic alteration of muscle fibers, which was, dynamically and
morphologically, indistinguishable from that caused by whole venom.
Effects of hemorrhagic toxin BaH-1 on endothelial cells (paper V)
The effects of BaH-1, a hemorrhagic metalloproteinase from B. asper venom,
on cultured endothelial cells, were studied. The toxin, despite its potent
hemorrhagic action in vivo, did not induce any significant cytotoxicity on the
capillary endothelial cells in vitro, even when concentrations as high as 65 µg/ml
were tested. The toxin per se did not interfere with the LDH assay utilized for the
assessment of cell damage. The main visible effect of toxin BaH-1 on endothelial
cells was a relatively slow, moderate detachment, with some of the cells becoming
round. This effect was clearly dose-dependent, but did not cause any intracellular
LDH release to the medium. In contrast, myotoxin II, which is devoid of
hemorrhagic activity, was cytotoxic to the endothelial cells, killing 100% of the
cells under similar assay conditions.
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Neutralization of Bothrops asper myotoxins by heparins (paper VI)
When whole B. asper venom was preincubated with either standard or LA-
heparin, and subsequently injected into mice, its myotoxic action was significantly
reduced in a dose-dependent manner. This result was confirmed by histological
evaluation and by the use of intravital microscopy. In the latter system, widespread
muscle fiber damage regularly developed 4-6 min after application of venom alone,
whereas, when it was mixed with standard or LA-heparin before application, muscle
fibers were protected throughout the observation period of 30 min. In contrast to
LA-heparin, standard heparin markedly increased the hemorrhage induced by the
venom, evident both histologically and intravitally.
The venoms of B. jararacussu, Agkistrodon p. piscivorus and Trimeresurus
flavoviridis, were also significantly neutralized by LA-heparin, regarding myotoxic
activity, as judged by the reduction in the serum CK levels measured at 3 hr.
However, the venoms of Crotalus durissus terrificus, C. viridis viridis, Naja naja
atra, and Vipera berus, were not neutralized.
Myotoxin II was cytolytic to L6 myoblasts and tEnd endothelial cells, in the
concentration range of 25-150 µg/ml. Endothelial cells were significantly more
susceptible than myoblasts to this cytotoxic action. Morphologically, both cell types
showed, after exposure to the toxin, an abundant cytoplasmic granulation, followed
by an apparent dissolution of the membrane, without detachment, similar to the
appearance of detergent-treated cultures.
When preincubated with myotoxin II, standard as well as LA-heparin blocked
its cytolytic activity on both cell types. Cells were completely protected at
approximate ratios of 0.02 and 0.3 µg heparin/µg myotoxin II, for L6 and tEnd cells,
respectively, with no observable differences in the inhibitory efficiency of the two
heparin types. Since the average molecular weight of both heparins utilized (15 kD)
is similar to that of myotoxin II, the heparin/toxin ratios expressed as µg/µg roughly
correspond to molar ratios. Under identical conditions, the neutralizing monoclonal
antibody MAb-3 was also able to inhibit the cytolytic action of myotoxin II,
completely preventing its effect at an approximate molar ratio of  1:1.
A complete neutralization of cytolysis caused by myotoxin II was also
achieved with heparan sulfate and low molecular weight heparin (Fragminâ),
although not with a variety of heparin-derived disaccharides or with chondroitin
sulfate. A non-anticoagulant heparin preparation of low molecular weight (LMW-
LA-heparin) also inhibited myotoxin II in vitro, although with a slight reduction in
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neutralization potency (Fig.3). On the other hand, pretreatment of the cells with
heparins, followed by washing, had no protective effect on myotoxin II-induced
cytolysis.
A significant inhibition of edema in the mouse footpad assay was achieved by
preincubation of myotoxin II with LA-heparin .
The heparin-binding components in B. asper venom were isolated by affinity
chromatography, eluting at approximately 0.5 M NaCl. SDS-PAGE of this fraction
showed a main band of 14-15 kD under reducing conditions, which corresponds to
the subunit molecular weight of myotoxins, and very small amounts of few other
components. Native cathodic PAGE showed that all described myotoxin isoforms
bound to the immobilized heparin column. Gel diffusion demonstrated that heparins
form a precipitable complex with venom myotoxins.
Since affinity chromatography and electrophoresis showed that heparin
interacts not only with myotoxin II, but also with other isoforms present in this
venom, the effect of heparins on the enzymatic and myotoxic activities of myotoxin
III was investigated. Both types of heparins significantly reduced the myotoxic
effect of this isoform in vivo, without inhibiting its enzymatic activity in an indirect
hemolysis assay.
The possible role of cell surface heparan sulfate in the mechanism of
cytotoxicity induced by myotoxin II was investigated. Both heparitinase and
chlorate treated L6 and tEnd cells were equally susceptible to myotoxin II, in
comparison with their respective controls. In agreement with this, myotoxin II
induced a comparable cytolytic effect in heparan sulfate defective mutant cells
CHO-pgsD-677 and CHO-K1 control cells.
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Figure 3: Neutralization of the cytolytic effect of B. asper myotoxin II
on cultured endothelial cells (tEnd) by preincubation with non-
anticoagulant heparin preparations of different molecular weight: LA-
heparin ~15 kD (filled circles), and low molecular weight-LA-heparin ~4
kD (open circles). Each point represents mean ± SD of duplicate assays.
LDH: lactic dehydrogenase.
Structural characteristics of the heparin-myotoxin interaction (paper VII)
The direct binding of 3H-labeled heparin to myotoxin II was measured by a
nitrocellulose filter binding assay. Myotoxin II bound almost all of the added
heparin in solution, in an unselective manner. The ability of different unlabeled
glycosaminoglycans (GAGs) to interact with myotoxin II was studied. When the
ability to compete with 3H-labeled heparin was tested, none of the GAGs was a
better competitor than heparin. Selective O-desulfation of heparin resulted in a
moderate decrease in the interaction, approximately two-fold for 6-O-desulfated
heparin, and six-fold in the case of 2-O-desulfated heparin. The interaction was
even weaker with the heparin desulfated at both 2-O and 6-O positions. Other
sulfated GAGs, such as dermatan sulfate and chondroitin sulfate, competed poorly
in the binding, only at concentrations about two orders of magnitude higher than
that of heparin.
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 Neutralization of the cytolytic activity of myotoxin II was in agreement with
both direct and inhibition binding data. Titration of the unmodified heparin
indicated a complete neutralization of toxin activity at the ratio of 1 µg
saccharide/µg protein or higher. Both 2-O- and 6-O-desulfated heparins were able
to neutralize the toxin at a ratio of 1 µg/µg, while no inhibitory effect could be
obtained with chondroitin sulfate or a low-sulfated heparan sulfate preparation, even
at ratios ten times higher than those required in the case of heparins.
The minimal size of heparin required to interact with myotoxin II was
determined both by direct binding of 3H-labeled oligosaccharides and by
neutralization of the cytolytic activity. The shortest heparin-derived
oligosaccharides interacting with the protein were hexasaccharides. The level of
binding increased proportionally to the saccharide length. In agreement with these
data, when unlabeled heparin-derived oligosaccharides were tested as myotoxin-
neutralizing compounds, at a ratio of 1 µg/µg of protein, hexasaccharides gave a
partial protective effect, octasaccharides showed an almost complete protection, and
decasaccharides or larger species blocked completely the cell-damaging activity of
the toxin.
Macromolecular complex formation was investigated by adding increasing
amounts of heparin to a myotoxin II solution, and then measuring the turbidity at
340 nm. Myotoxin II alone did not absorb light at this wavelenght. A maximal
turbidity was obtained at a ratio of 0.2 µg heparin/µg protein (5 protein
molecules/heparin chain), being constantly diminished by further additions of
heparin.
Since both heparin and the monoclonal antibody MAb-3 neutralize the
cytotoxic activity of myotoxin II, the possible competition between these two
molecules for toxin binding was investigated using an enzyme-immunoassay.
Results showed that heparin, even at very high concentrations, was not able to
inhibit the binding of MAb-3 to myotoxin II. As a control, a polyclonal antivenom
preparation competed with MAb-3 in a dose-dependent mode.
A synthetic peptide corresponding to the N-terminal 26 amino acids (described
as a heparin-binding site of porcine pancreatic PLA2) of myotoxin II  was tested for
its ability to bind heparin. No significant heparin binding was observed in the filter
assay, despite that the peptide could bind to the nitrocellulose filter. Moreover, in
the cytotoxicity assay, the presence of peptide (up to 275 µg/ml) did not affect the
neutralizing activity of heparin towards myotoxin II. The peptide itself did not have
any cytotoxic effects even at these high concentrations.
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GENERAL DISCUSSION
The purpose of the present work was to characterize the local tissue damage
and inflammatory reactions induced by snake venoms and toxins, to develop new
methods for the study of tissue-damaging venom components, and, finally, to find
and characterize potentially neutralizing agents to these toxins.
Inflammation is a major feature of envenomations by many snake species, yet
its possible contribution in the pathogenesis of venom effects, or, on the other hand,
its possible antagonisms to toxic actions, have received relatively little attention.
One reason for this has probably been the intrinsic complexity of inflammation as an
integrated physiological process. Nevertheless, a precise understanding of the
inflammatory events that follow envenomation, and their roles, could lead to the
development of better therapeutic strategies, complementary to conventional
serotherapy (Hanson, 1991).
We investigated the host response to Bothrops asper venom in a mouse model,
with particular emphasis on edema, leukocyte infiltration, and the possible
participation of cytokines as mediators of this inflammatory process (paper I).
Two types of edema responses to the venom were observed. At low doses (i.e.
1 µg), a rapid but transient edema developed, in the absence of hemorrhage, and
with a scarce leukocyte infiltrate in the injected footpad. At this low dose, probably
only the true permeability-increasing components of the venom are being detected,
in the absence of additional contributing factors. However, at higher venom doses
(i.e. 50 µg), more representative of the clinical and pathological picture observed
after snakebites, there was a similarly rapid edema, but it was sustained over a much
longer period. In this case, the edema was accompanied by hemorrhage,
myonecrosis, and abundant leukocyte infiltration. The duration of the edema was
related to the dose of venom injected (paper I). A similar finding was made in the
study of the edema induced by the venom of Vipera berus (paper II). Although both
observations strictly correspond to an animal model, they support the concept that
the magnitude and duration of local edema could be simple and useful parameters
for the estimation of severity of envenomation by crotalids in humans.
Leukocytes infiltrated the tissues within 3-6 hr after venom injection, the
predominant type being the neutrophil (paper I). This infiltrate peaked at 24 and 72
hr and declined thereafter. Mononuclear phagocytes were also observed at these
later times, but relatively few lymphocytes appeared in the inflamed footpad tissues.
The scarcity of infiltrating lymphocytes is in agreement with the report of Emslie-
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Smith and Harris (1989) in the inflammatory response induced by notechis II-5, a
myotoxic PLA2 of Notechis scutatus venom, in the rat. In our studies, the
appearance of a cell infiltrate was independent of the hemorrhagic action of the
venom, since it could be observed after injection of (a) venom that was partially
preneutralized with antivenom, in the absence of hemorrhage, and (b) purified
myotoxin II. This suggests that myonecrosis is, at least in part, responsible for the
extravasation of neutrophils and mononuclear phagocytes into the tissues. The
kinetics and cell composition of this inflammatory response appeared similar to that
previously described after the injection of N. scutatus (Harris and Johnson, 1978)
and B. asper (Gutiérrez et al., 1986f) venoms into skeletal muscle. Phagocytes have
been commonly found in areas of myonecrosis induced by venoms or toxins, and are
important in the removal of dead cells and debris in the process of muscle
regeneration (Harris et al., 1975; Queiroz et al., 1984; Kouyoumdjian et al., 1986;
Ownby, 1990; Harris and Cullen, 1990; Gutiérrez et al., 1984c, 1986d, 1990b; Sharp
et al., 1993). Moreover, phagocyte-derived enzymes probably participate in the
degradation of myofibrillar proteins after myonecrosis (Pluskal et al., 1978;
Gutiérrez et al., 1990b).
Several hematological alterations occurred after venom injection (paper I).
Circulating platelets abruptly decreased, and did not normalize until 12 hr later. This
finding is in agreement with intravital microscopic observations of platelet thrombi
forming on venular walls shortly after exposure to venom (paper IV).
Thrombocytopenia can frequently occur in human envenomations by snakes (Russell
et al., 1975; Warrell et al., 1976b; Reid and Theakston, 1983; Kamiguti et al.,
1991b, 1992; Benbassat and Shalev, 1993; Cardoso et al., 1993). In a clinical study
of eighteen patients bitten by B. asper, no significant changes in platelet counts were
found, despite the marked alterations in coagulation parameters (Barrantes et al.,
1985). Although species differences cannot be ruled out, the discrepancy with our
findings may be due to the time in which samples were analyzed: in the patients,
tests were performed between 2 and 24 hr after the snakebite, and, at least in our
mouse model, platelet numbers had already normalized 12 hr after venom injection.
A similar reason may also explain the findings in a case of juvenile B. asper bite, in
which the dramatic coagulation alterations were not accompanied by a decrease in
platelet numbers: the patient was first evaluated 20 hr after the accident (Kornalík
and Vorlová, 1990).
In the case of B. asper venom, it remains to be determined which component(s)
is(are) responsible for the thrombocytopenic effect. Hemorrhagic toxins, by inducing
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important endothelial cell damage in vivo (Ownby et al., 1978, 1990; Ownby and
Geren, 1987; Kamiguti et al., 1991a; Moreira et al., 1994) would be likely
candidates. A hemorrhagic fraction isolated from B. jararaca venom was capable of
inducing a marked thrombocytopenia in rats after 2 hr (Kamiguti et al., 1991a),
similar to the effects described in our experiments with crude B. asper venom.
Unfortunately, the small amounts of purified hemorrhagic toxin BaH-1 available
(paper V) precluded our possibilities to evaluate this hypothesis by intravital and
hematological analyses.
Regarding cytokine involvement in venom-induced inflammation, a significant
increase of serum IL-6 concentration was observed soon after injection, while no IL-
1a and TNF-a increases were detected (paper I). Preliminary immunohistochemical
data indicate, however, that some local IL-1a production in response to
envenomation may occur (unpublished data). This cytokine response pattern is
similar to that observed in acute trauma conditions (Cruickshank et al., 1990; Hoch
et al., 1993) and thus, might be an indirect response to the tissue damage caused by
various venom components. Indeed, the IL-6 serum peak was induced not only by
the whole venom, but also by the injection of (a) isolated myotoxin II or (b)
hemorrhagic toxin BaH-1, suggesting that myonecrosis and endothelial cell damage
could both be initial stimuli for the IL-6 response. These observations, together with
the inability of venom to stimulate IL-6 release from splenocytes (containing
macrophages, T and B lymphocytes) in vitro, strongly suggest that the IL-6
production is triggered in response to cell damage. Other snake venoms tested, such
as Vipera berus and Crotalus v. viridis, also elicited high IL-6 responses, showing
that this phenomenon is not unique to B. asper venom, but probably a common
feature of tissue-damaging venoms.
The cell type responsible for IL-6 release in vivo in the present model, as well
as the signaling mechanisms involved, are not known. Indeed, surprisingly little is
known about the primary signals that trigger IL-6, and the subsequent acute-phase
response, in non-infectious conditions involving tissue damage (Koj et al., 1993).
Our pilot in vivo experiments exploring the possible role of complement in the
signaling for IL-6 release, after muscle necrosis induced by myotoxin II, were
negative. In vitro, the small, but significant increase in IL-6 release by endothelial
cells treated with B. asper venom and myotoxin II, could be suggestive of a role of
this cell type in vivo. However, these results must be interpreted with caution.
Although both agents were tested at subcytolytic doses, further experiments showed
that myotoxin II exerts membrane-permeabilizing effects on this and other cell types
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(papers V and VI), and thus, the small increase of IL-6 in culture supernatants may
well be the result of a minor, undetected, cell membrane damage, rather than a direct
induction of IL-6 synthesis and secretion. Analyses at the level of IL-6 mRNA
would be necessary to discern between the two possibilities.
To our knowledge, this is the first report dealing with the evaluation of
proinflammatory cytokines in the response to snake venoms. Our findings in the
mouse model are in agreement with the results recently obtained in a collaborative
clinical study of snakebites by Bothrops spp. and Crotalus durissus terrificus from
Brazil (Barraviera, Lomonte, Tarkowski, Hanson, and Meira, manuscript submitted).
In the sera of these patients, IL-6 elevations were frequently observed , together with
IL-8 (not analyzed in the present work), while some IL-1b and no TNF-a increases
could be detected. An increase in IL-6 levels could explain the transient
lymphopenia and leukocytosis observed both in mice (paper I) and in these snakebite
patients, since this cytokine is capable of increasing adrenocorticotropic hormone
and glucocorticoid secretion (Castell et al., 1989). Lymphopenia has also been
described after injection of notechis II-5 from Nothechis scutatus venom (Emslie-
Smith and Harris, 1989). Our observations on the rapid IL-6 response induced after
venom or myotoxin II-induced myonecrosis may explain the findings of these
authors.
IL-6 is known to be an important signal for inducing the synthesis of acute-
phase proteins in the liver (Mackiewicz et al., 1988; Castell et al., 1989; Lewis et
al., 1992). Several of its actions might be beneficial in the pathological situation
induced by snake venoms. Speculatively, the increased anti-protease production by
hepatocytes might inhibit some venom proteases, as well as endogenous enzymes
activated and released during inflammation. Although we did not observe a
neutralizing effect of purified human a2-macroglobulin when preincubated with
crude B. asper venom, the interaction of this proteinase inhibitor with pure
hemorrhagic toxins from Crotalus atrox venom has been demonstrated (Baramova et
al., 1990b). Similarly, fibrinogen synthesis increase may compensate the fibrinogen
consumption caused by the venom (Barrantes et al., 1985; Gené et al., 1989). IL-6
can increase platelet numbers (Hirano et al., 1990), and thus, may be responsible for
the observed normalization of this parameter at 12 hr, just after the cytokine peak
(paper I). IL-6 can stimulate the division of myoblasts in vitro (Austin and Burgess,
1991), and thereby could have a role in the process of regeneration of skeletal
muscle after necrosis. IL-6 is known to induce renal mesangial cell proliferation
(Roitt et al., 1993), a pathological finding that has been described after the injection
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of Trimeresurus flavoviridis (Barnes and Abboud, 1993) and Bothrops jararaca
(Rezende et al., 1989) venoms. However, all these possible actions of IL-6 are
theoretical. We attempted to detect a possible induction of acute-phase reactants
with anti-hemorrhagic activity in the mouse, by IL-6 injection and subsequent
quantitative assay of hemorrhage induced by B. asper venom. However, this pilot
experiment failed to show any reduced hemorrhage in mice receiving the cytokine 6
hr before the venom, in comparison to untreated controls. Although the recombinant
IL-6 utilized was of human origin, it is known to be active on murine cells (Van
Snick, 1990). An extremely valuable tool for future studies of the possible roles of
this cytokine in envenomation models, will be the recently developed mouse strain
with a targeted IL-6 gene deletion (IL-6 "knock-out" mouse).
As in other models of tissue damage and inflammation, these two processes are
intimately related, making it difficult to determine the extent to which inflammatory
reactions are causes or effects of damage, or the delineation between detrimental or
beneficial consequences to the host. At least one possible cytokine with known
tissue damaging ability, TNF-a (Dinarello, 1992), could not be demonstrated in this
model. However, still many potent inflammatory mediators with destructive abilities
remain to be investigated in relation to the local tissue damage caused by venoms.
A tentative scheme summarizing some of the events and interactions during
local tissue damage and inflammatory responses induced by snake venoms, is
depicted in Fig. 4. This general scheme constitutes only a personal view of the
process, and it should be emphasized that is partly hypothetical, as some of the
possible interactions and effects have not been specifically documented, and
important variations are expected depending on different venoms, etc.
A powerful tool in the study of acute local tissue damage and inflammatory
reactions induced by venoms, as well as in many other pathological entities, is the
use of intravital microscopy techniques (Menger and Lehr, 1993). The effects
induced by particular isolated toxins can be compared to those caused by the whole
venom, in order to dissect the complex series of reactions occurring in vivo. In this
investigation, the characteristics of the early pathological alterations caused by B.
asper venom and myotoxin II were microscopically analyzed in the cremaster
muscle of live mice (paper IV). The immediate muscle fiber contractions occurring
after contact with venom or myotoxin II, are in agreement with the notion that
myotoxins act initially on the sarcolemma, altering its permeability and allowing a
calcium influx. However, other possible causes for this effect cannot be ruled out.
Blood flow disturbances were evident in the tissue microcirculation, and were
56
caused by a combination of factors, including: (a) thrombotic activity on the walls of
venules (but not arterioles); (b) marked stasis and hemoconcentration, concomitant
to the abundant plasma leakage visualized by FITC-dextran extravasation; (c) shape
changes of the erythrocytes such as crenation and sphering, altering their rheological
properties; and (d) microvessel damage and hemorrhage. Interestingly, however, in
many cases the blood flow through a ruptured microvessel continued after the
bleeding had stopped (in about 10-20 sec). All these mechanisms affecting blood
flow probably play a role in the development of ischemic conditions leading to
further, secondary muscle necrosis of slower onset, in addition to the direct and
rapid muscle fiber damage induced by venom myotoxins.
The early morphological manifestations of the process of muscle fiber damage
were observed (paper IV), and were similar in the case of whole venom and purified
myotoxin II. The degeneration of individual fibers appeared initially as a focal loss
of striation, seen as a narrow band across the entire fiber width, and was followed by
the appearance of a small wedge-shaped lesion at one edge, retraction of the
myofibrils in opposite directions, and widening of the gap until a complete rupture
had occurred. The process could be gradually repeated at several sites along the
same fiber, leaving in the end a row of amorphous fragments separated by
apparently empty spaces. Interestingly, at a relative short distance from cellular
rupture sites, normal striations were still visible, until the process also spread into
these areas. Therefore, muscle fiber damage caused by myotoxin II or venom, does
not develop as a homogeneous degeneration of the whole fiber or large parts of it,
but has a markedly focal character. Again, this observation is in agreement with the
notion of a rapid, membrane-acting mechanism of myotoxins.
Also intravitally, it was possible to determine that the main targets of the
hemorrhagic process caused by the venom are microvessels, in the size range of
capillaries and small venules (paper IV). The explosive character of the erythrocyte
extravasation process is in agreement with the concept of hemorrhage per rhexis.
This was also supported by electron microscopic observations of the affected
vessels, showing gaps in the endothelial wall, through which erythrocytes escaped.
The in vivo mechanism of action of hemorrhagic toxins has not been
completely established. While considerable evidence points out to a mechanism
based on the proteolytic degradation of the basal lamina of microvessels as the key
event, notorious degenerative changes in endothelial cells also occur, and therefore
the possibility that hemorrhagic toxins might have direct damaging effects on this
cell type has been speculatively suggested (Ownby and Geren, 1978; Ownby et al.,
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1990; Gutiérrez and Lomonte, 1989). Our in vitro results with BaH-1 purified from
B. asper venom showed that this hemorrhagic toxin was only able to cause
detachment of cultured capillary endothelial cells from the substrate, probably due to
proteolytic digestion of extracellular matrix components, but without any detectable
loss of membrane integrity, as evaluated by the release of intracellular LDH (paper
V). These findings indicate that BaH-1 is not directly cytotoxic to endothelial cells,
and that their degeneration in vivo should be the result of an indirect mechanism,
perhaps initiated by the proteolytic degradation of their surrounding basal lamina by
the hemorrhagic metalloproteinases. Our conclusions are in contrast with a recent
paper reporting that purified hemorrhagic toxins from Crotalus atrox and C. ruber
ruber venoms exert direct cytotoxic action on human endothelial cells in culture
(Obrig et al., 1993). The conclusion of these authors is based on the decreased
neutral red uptake by cells, after 24 hr (for HT-1 and HT-2 of C. ruber ruber) or 72
hr (for HT-a and HT-d of C. atrox) of exposure to the toxins. However, their
cytotoxicity assay utilized two washing steps of the cultures, and thus, it is not clear
if the resulting decreased color signal reflects a true cytotoxic effect, as stated by the
authors, or a loss of cells due to proteolytic detachment from their substratum.
Unfortunately, in their study no attempt was made to describe morphological
changes, including detachment, in the cultures treated with the hemorrhagic toxins
(Obrig et al., 1993). We have shown that detachment is an evident phenomenon in
the case of BaH-1 of B. asper, implying that the evaluation of direct cytotoxic
effects of hemorrhagic toxins should be performed by techniques that avoid washing
steps, such as by measuring the release of intracellular markers, or other signs of
rapid cell damage, that would be compatible with the in vivo observation of capillary
disruption within the range of minutes (paper IV).
Our intravital observations of the tissue damage induced by B. asper venom
confirm and extend the prevalent notion (Ohsaka, 1979; Gutiérrez and Lomonte,
1989; Ownby, 1990) that the toxins responsible for myonecrosis, hemorrhage, and
edema, act very rapidly. All these damaging processes were recorded intravitally
within only a few minutes after exposure of  the tissues to venom (paper IV). This
dramatic speed poses a formidable challenge to the search of therapeutical measures
that could prevent, or at least, significantly reduce, the tissue damage in human
victims of snakebites.
The screening and experimental evaluation of useful neutralizing drugs, as well
as the development of improved neutralizing antisera against tissue-damaging toxins,
require simple and accurate methods for the quantitative estimation of edema,
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hemorrhage, and myonecrosis. While simple methods for edema and hemorrhage
quantification are well established, the estimation of muscle damage poses more
difficulties. Quantitative histological analysis is ideal, and is currently facilitated by
modern computer-assisted microscopic image analyzers. However, even in its
simplest forms, quantitative histology is time-consuming, and requires considerable
equipment. As an alternative, biochemical methods based on the release of muscle-
specific markers, such as creatine kinase (CK), have been utilized.
In this work, we developed a new biochemical assay for the quantification of
myonecrosis (paper III), exploiting the known ability of live cells to reduce the
tetrazolium compound MTT into a colored formazan product, a reaction commonly
utilized in cell culture viability assays (Denizot and Lang, 1986). Other tetrazolium
salts, such as nitroblue tetrazolium, have been used to quantify the areas of necrosis
in tissue sections of myocardium (Klein et al., 1981), and skeletal muscle, in
combination with computerized planimetry of the staining pattern (Labbe et al.,
1988). We found that gastrocnemius muscle homogenates prepared in the presence
of 1% Triton X-100, retained the ability to reduce MTT, and that the purple
formazan product remained in solution, allowing the direct spectrophotometric
measurement of color intensity. The usefulness of this technique in the estimation of
myonecrosis was investigated using the venom of Micrurus nigrocinctus, which
exerts potent myotoxicity in the absence of other tissue-damaging effects such as
edema and hemorrhage (Gutiérrez et al., 1983). The results of the MTT-reduction
assay were compared, by a dose-response analysis, to those obtained by quantitative
histological analysis (taken as the reference method), and by two methods based on
the quantification of CK activity, in muscle or in plasma, respectively. The residual
MTT-reducing activity of muscle rapidly decreased after venom-induced
myonecrosis, and the values measured at 24 hr showed a good correlation with the
myonecrosis index obtained by quantitative histology. On the other hand,
determination of residual CK activity in muscle seemed to overestimate
myonecrosis, since with some venom doses, CK activity was almost totally depleted
in muscles that still contained a proportion of unaffected fibers, according to the
histological reference method.
An interesting observation regarding the use of plasma CK activity was the
finding that at high venom doses, where there was virtually a complete myonecrosis
(and CK activity depletion) of the injected gastrocnemius, plasma CK levels
continued to rise. This implies that at high venom doses, CK release occurs not only
at the site of injection, but also at adjacent or distant sites. Thus, plasma CK levels
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probably reflect both local and systemic myotoxicity, this property representing an
advantage in cases where systemic muscle damage is to be evaluated. However,
potential problems of the use of CK as an estimator of muscle damage have been
pointed out, such as the possibility of enzyme release in muscle fibers that are not
necessarily damaged in an irreversible fashion (Suarez-Kurtz, 1982; Ownby et al.,
1982).
The validity of the MTT-reducing technique for the quantification of
myonecrosis induced by other venoms and myotoxic agents remains to be evaluated,
and is currently under study. In particular, it is still not known how other tissue
alterations occurring concomitantly with myonecrosis, such as hemorrhage and
edema, may affect its performance. At least in the case of Vipera berus venom, we
observed a fair correlation between muscle damage estimated by plasma CK levels
and muscle MTT-reducing activity (paper II).
In addition to in vivo techniques for the experimental estimation of
myonecrosis, in vitro assays utilizing cell cultures could be extremely useful models
for the study of myotoxins, their mechanism of action, and neutralization. In
particular, cell culture assays would significantly reduce the use of experimental
animals in this field of research.
In the course of this investigation, it was observed that B. asper myotoxins
exhibited cytotoxic activity not only on cultured skeletal muscle myoblasts, but also
on several other cell types, including capillary endothelial cells (papers V and VI).
Endothelial cells were more susceptible than myoblasts to the cytolytic action of
myotoxin II. A simple, non-isotopic cytotoxicity assay, based on the release of lactic
dehydrogenase (LDH) from damaged cells was adapted for the in vitro study of
these myotoxic PLA2s and their neutralization by different types of agents.
Heparin, previously reported to be able to inhibit the myotoxic action of B.
jararacussu venom (Melo and Suarez-Kurtz, 1988), was also found to be a potent
inhibitor of the cytolytic action of B. asper myotoxins in vitro, and as well, to
neutralize their muscle damaging activity in vivo (paper VI). However, a significant
limitation in the use of heparin as a neutralizing agent, is its potent anticoagulant
action, which may potentiate the hemorrhage caused by Bothrops venoms, both due
to their potent hemorrhagic toxins and to their ability to affect coagulation
(Mandelbaum et al., 1984; Selistre et al., 1990; Kamiguti et al., 1991a, 1992;
Ouyang et al., 1992; Borkow et al., 1993). Therefore, we evaluated the neutralizing
ability of non-anticoagulant heparin, obtained after affinity chromatography on an
immobilized antithrombin support (LA-heparin). It was found that the neutralizing
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ability of heparin did not depend on its anticoagulant activity. Thus, LA-heparin
represents an interesting possibility for the inhibition of myotoxins in snakebite
envenomations.
In screening for the effects of LA-heparin on the myotoxic activity of different
venoms, it was found that B. jararacussu and Trimeresurus flavoviridis venoms
were also susceptible to this inhibition, the former confirming the original report by
Melo and Suarez-Kurtz (1988). However, no inhibition was observed in the case of
other venoms tested, also containing highly basic myotoxins. The three venoms
neutralized contain PLA2 myotoxins that have been well characterized, displaying a
high structural homology (Yoshizumi et al., 1990; Liu et al., 1990; Francis et al.,
1991; Cintra et al., 1993) and immunological cross-reactivity (Lomonte et al.,
1990c).
These results suggested that the observed interaction between heparins and
myotoxic PLA2s could be based not only on a non-specific electrostatic attraction
due to the basic character of the enzymes, but that some specific recognition
component might additionally be involved. Further structural analysis of the
interaction between heparins and myotoxin II (paper VII), showed that the binding
does not occur via specific heparin sequences (i.e. as with antithrombin; Lindahl et
al., 1984), but rather that it depends on cooperative electrostatic interactions
involving both N-sulfates and O-sulfates (in 2-O and 6-O positions), the binding
efficiency being proportional to the heparin chain length and the overall sulfation.
Nevertheless, some specificity for a heparin/heparan sulfate "backbone" in this
interaction was suggested by the very weak binding obtained with other highly
sulfated GAGs, such as chondroitin sulfate and dermatan sulfate, indicating that a
high negative charge is not the only requirement for binding.
The minimal heparin chain lenght capable of interacting with myotoxin II was
at the hexasaccharide level, and a good correlation was obtained between the
binding and neutralization of cytolytic action. Since molecular weight is important
for the pharmacokinetic properties of heparins (Bergonzini et al., 1992), these
observations suggest that future evaluations of the neutralizing ability of heparin
should consider the use of shorter non-anticoagulant fragments (i.e. LMW-LA-
heparin, Mr 4-5 Kd) in addition to LA-heparin (Mr 15 Kd).
Studies on the binding and neutralization of B. asper myotoxins with heparins
provided two interesting basic observations concerning the structure-function
relationship of these toxins. First, heparin neutralized the myotoxic action of
myotoxin III, without affecting its PLA2 activity, showing another clear example of
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the dissociation between these two actions. Second, the lack of competition between
heparin and MAb-3, a neutralizing monoclonal antibody, for the binding to
myotoxin II, suggests that both molecules interact with different toxin sites, and
therefore, that two different mechanisms for the inhibition of toxic activity exist.
The N-terminal 26 amino acid residues of porcine pancreatic PLA2 have been
shown to interact with heparin (Diccianni et al., 1991). We could not detect any
interaction between heparin and a 26-mer synthetic peptide of the homologous
region of myotoxin II, suggesting that the interaction probably occurs via a different
protein site than in pancreatic PLA2. Other myotoxin protein regions are currently
being evaluated in order to identify the possible heparin binding site. We postulated
that heparins should bind to a strongly cationic toxin site, likely to be involved in the
recognition of negatively-charged cellular target sites (Díaz et al., 1991; Rufini et
al., 1992), and thereby inhibiting the cytolytic action.
Despite the potent inhibitory effect of heparins on the in vitro cytolytic action
of myotoxic PLA2s, in vivo neutralization of myotoxicity by preincubation tests was
less efficient (paper VI). Several possibilities exist to explain this finding, but further
work is needed to analyze them. It is likely that high affinity heparin-binding factors
compete with myotoxins in vivo, reducing its interaction with heparin. The similar
neutralizing efficiency of MAb-3 against myotoxin II in vivo (myotoxicity) and in
vitro (cytolytic effect), suggests that the observed difference in the case of heparins
may not be due to the cell culture model utilized. Future work will assess the
neutralizing efficiency of LA-heparins in vivo, by independent administration tests,
in comparison to antivenoms, or mixtures of antivenom and heparins. Preliminary
observations in the mouse model (unpublished data) indicate that there may be a
partial, but significant reduction of muscle damage by early administration of LA-
heparin.
Figure 4: A hypothetical general scheme of some events and interactions in the local tissue
damage and inflammatory responses induced by snake venoms. The filled arrowheads denote
documented effects, while empty arrowheads denote possible effects. Dashed lines with empty
arrowheads indicate inhibitory or counteracting effects.
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